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Background: Allergic rhinitis is a major risk factor for asthma devel-
opment. Lower airway inflammation and remodeling have been 
observed in allergic rhinitis subjects without asthma. Tissue repair 
processes involve the production of extracellular matrix, in which 
fibroblasts play a major role. These cells originate from bone marrow 
progenitors called fibrocytes. The number of fibrocytes is increased 
in asthmatics following allergen exposure. In allergic rhinitis, aller-
gen-induced inflammation has been widely observed, but studies on 
allergen-induced lower airway remodeling are still limited. The aim of 
this study is to determine the effect of seasonal allergen exposure on 
the profile of fibrocytes isolated from blood of allergic rhinitis subjects 
without asthma.
Methods: Non asthmatic subjects with seasonal allergic rhinitis were 
recruited. At baseline (out of the pollen season), medical history, skin 
prick tests, spirometry, methacholine bronchoprovocation, blood 
sampling and sputum induction were performed. At the peak of rhi-
nitis symptoms, the tests were repeated. Fibrocytes number and level 
of activation were determined in whole blood. Cells were stained for 
fibrocyte markers (CD34, CD45, CXCR4, collagen I) and analyzed by 
flow cytometry.
Results: Thirty subjects (18F:12M) aged 28 ±  8  years were recruited. 
Among the 12 subjects that completed the study yet, there were 
12.2 ± 7.9 % of fibrocytes at baseline, whereas there were 7.1 ± 3.6 % 
of fibrocytes during the pollen season. Mean fluorescence of CXCR4 
was 1614 ±  646 (arbitrary units) at baseline and 1805 ±  770 during 
the pollen season.
Conclusion: The observed decrease in fibrocytes during allergy sea-
son may indicate an active migration of these cells from the periphery 
to the airways. A change in the number and profile of fibrocytes dur-
ing natural seasonal exposure in non-asthmatic rhinitic subjects may 
help direct further studies looking at future outcome of these patients 
to develop a predictor of asthma onset.
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Background: Sensitization to common environmental aeroallergens 
plays a significant role in the pathogenesis and severity of respiratory 
allergic disorders [1, 2].Understanding sensitization patterns helps cli-
nicians tailor care more effectively. This is the first study looking at sen-
sitization patterns in Northern Alberta.
Methods: Retrospective chart review of skin prick test (SPT) results for 
11 environmental aeroallergens performed between January 1st to 
June 30th 2014 at a University-based lab and clinic, where patients are 
referred for SPT by allergists, respirologists, general practitioners and 
ENT specialists. Data was analyzed descriptively and bivariate analyses 
by sex were done.
Results: A total of 623 patients (36.9 % males; 63.1 % females), aged 
4–84 years (mean age 38.6 years) had SPT, of which 438 (70.3 %) had 
a positive test for at least one aeroallergen (atopy). There were no 
significant sex differences in the frequency of atopy (males: 71.3  % 
versus females: 69.7  %; p  =  0.373). The frequency of sensitivity to 
particular allergens among atopic subjects was: cat (53.1  %), house 
dust mite (50.3 %), grass (39.2 %), birch (23.7 %), alternaria (23.7 %), 
dog (17.3 %), poplar (12.1 %), cedar (9.6 %), aspergillus (9.6 %), hor-
modendrum (8  %), and penicillium (6.2  %). Of 438 atopic patients, 
110 (25.1 %) were mono sensitized, 199 (45.4 %) oligosensitized (2–3 
allergens), and 129 (29.5 %) polysensitized (≥4 allergens). There were 
no significant sex differences in monosensitization (males: 22 % ver-
sus females: 27  %; p =  0.143) and oligosensitization (males: 40.9  % 
versus females: 48.2  %; p  =  0.082) rates. Polysensitization was sig-
nificantly more frequent in males (37.2  %) than in females (24.8  %; 
p = 0.004).
Conclusion: Cat is the most frequent perennial allergen and grass 
the most frequent seasonal allergen in Northern Alberta. There 
was no significant difference in the frequency of atopy between 
males and females. However, males were more likely to be poly-
sensitized than females. Further studies are needed to investi-
gate sensitization patterns among patients with specific allergic 
conditions.
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Background: Adolescents with FIA are more likely to experience fatal 
anaphylaxis [1] and must learn to independently manage living with 
FIA and its stigma [2, 3]. These adolescents must make health deci-
sions regarding FIA and personal safety, often using information from 
Health Care Providers (HCPs). Many studies use risk objectively as a 
probability, however risk is primarily influenced subjectively by indi-
vidual context and perception [4]. As a concept used in health educa-
tion, risk is not well-defined. Using risk objectively when addressing 
health may cause marginalization and reduced health care participa-
tion for adolescents [5, 6]. Therefore discussing risk in terms of what is 
acceptable for individuals may improve management of FIA. The con-
cept of acceptable risk must be defined for HCPs empowering adoles-
cents with FIA to have the agency to live within their defined levels of 
wellness.
Methods: Walker and Avant’s [7] method for concept analysis was 
used to analyze and define the concept of acceptable risk in the con-
text of adolescents with FIA.
Results: Acceptable risk involves active decision-making for modifi-
able possibilities where individuals perceive risk and are able to decide 
whether a situation is safe enough. Using acceptable risk may help to 
highlight perceived differences in acceptability of risk, and aid in mod-
ifying the acceptability of risk levels.
Conclusions: The unpredictability and severity of FIA means the abil-
ity to manage and cope with risk is important for improving quality 
of life and safety for adolescents living with FIA. HCPs should address 
acceptable risk based on individual definitions to engage in and mod-
ify perceptions of acceptable risk in daily life. Using acceptable risk to 
clarify discussions about health management in chronic illness may 
improve coping, facilitate conversations about safety, reduce shame 
when unable to comply with ideal management, and empower ado-
lescents living with FIA to take active roles making health decisions.
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Chronic granulomatous disease (CGD) is a life threatening immune 
deficiency caracterized by severe bacterial or fungal infections, and 
granulomatous inflammation. The only curative treatment is a hemat-
opoietic stem cell transplantation (HSCT). In 2010, seven children 
from Sainte Justine hospital were included in an international initia-
tive of HSCT for CGD, based on a reduced toxicity conditioning (RTC), 
followed by seven others transplanted after the completion of the 
study.
Data were retrospectively extracted from medical charts for 14 consec-
utive children transplanted for CGD from 2010 to 2014. Donors were 
a matched sibling (3/14), or a matched unrelated donor (11/14). The 
RTC consisted of Fludarabine, targeted Busulfan and rabbit Antithymo-
globulin or Alemtuzumab.
The median age at HSCT was 15  years (1–20). Previous history of 
severe infections included abscesses located in adenopathy (9/14), 
skin (8/14), liver (7/14) or lungs (10/14), with pulmonary aspergillosis 
proven for five patients. Septicemia (4/14) and osteomyelitis (2/14) 
were also common. Inflammation mainly presented as Crohn like coli-
tis (5/14) and chronic lung inflammation (6/14). Three patients had 
received granulocytes transfusions previously. None patient had active 
infection or inflammation at the time of transplantation.
All 14 patients engrafted. Severe (grade 3–4) acute graft versus host 
disease (GVHD) and chronic extensive GVHD were not observed. 
Three patients experienced immune haemolytic anemia (3/14) and 
nephrotic syndrome (1/14).
The main complication was secondary graft failure for 3/14 patients 
occurring at 6 months. All three patients engrafted durably after a sec-
ond HSCT. Including second grafts, post 6 months after HSCT, chimer-
ism was higher than 90 % in 13/14 patients and 66 % in one patient. 
With a median follow-up of 43  months (7–60), all patients are alive, 
cured from CGD and free from immunosuppressive drugs.
HSCT with a RTC and a matched unrelated donor is safe and effective 
for children with severe forms of CGD.
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Background: Severe combined immunodeficiency (SCID) is a life-
threatening condition that can be treated by allogeneic hematopoi-
etic stem cell transplantations (HSCT), gene therapy or adenosine 
deaminase (ADA) replacement. Early diagnosis of SCID might improve 
patients’ outcome. Newborn screening (NBS) for SCID was initiated 
in Ontario in August 2013, however the impact on patients is largely 
unknown.
Methods: We analyzed all patients diagnosed with SCID between 
January 2005 and July 2013 (pre-NBS group) or between August 2013 
and June 2015 (post-NBS group) who were referred to the Hospital for 
Sick Children, Toronto. The SCID aetiology, age of diagnosis, number of 
infections, length of hospital admissions prior to definitive treatment, 
age of definitive treatment and survival were compared using Fisher 
exact test and student’s t tests, when appropriate.
Results: Table  1 lists the aetiology of SCID in 21 pre-NBS and 6 
post-NBS patients. Pre-NBS, SCID was identified at a mean age of 
5.6  months compared to 0.42  months post-NBS (P  <  0.0001). Post-
NBS patients had less infections (1.3/patient versus 3.9/patient, 
P  <  0.01) and shorter admissions prior to definitive treatment 
(mean 27.3 versus 113.8  days, P  <  0.001). Pre-NBS, three patients 
received ADA replacement followed by gene therapy in one patient, 
while 18 patients received HSCT. Post-NBS, ADA replacement 
was given to 4 patients followed by gene therapy in two patients, 
while two patients received HSCT. Definitive therapy post-NBS 
was given at a younger age compared to pre-NBS (mean 61.5 ver-
sus 248  days, P  <  0.0001). All post-NBS patients survived (range 
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5–23  months) compared to 71  % survival in the pre-NBS group 
(range 28–121 months).
Conclusions: The time to SCID diagnosis and treatment was signifi-
cantly shorter post-NBS. Less infections and shorter hospital admission 
prior to treatment occurred post-NBS. Longer follow up and additional 
patients are needed to better appreciate the impact of NBS on the 
diagnosis, management and outcome of SCID.
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Background: Regulatory B cells (Bregs) have the capacity to regulate 
and suppress immune responses through production of IL-10 cytokine 
and IgG4 antibodies. The study of Bregs in asthma and allergy is a grow-
ing field, but few papers have reported on Bregs in allergic asthmatics. 
We previously reported that allergic asthmatics have lower levels of 
circulating Bregs compared to healthy controls. No studies have exam-
ined the level of Bregs in the airways.
Methods: Allergic asthmatics (AA), allergic non-asthmatics (ANA) 
and healthy controls (HC) donated expectorated sputum samples 
for Breg analysis. Sputum was induced by inhalation of 3, 4 and 5 % 
nebulized saline at 7-minute intervals, and cells were isolated from 
selected mucous plugs and stained with CD5, CD19, CD45, IL-10 
and FoxP3. Cells were acquired using a Becton–Dickinson LSRII 
flow cytometer, analyzed using FlowJo and data were expressed as 
mean ± SEM. Lymphocytes were characterized as SSClowCD45+ and 
B cells were characterized as SSClowCD45+CD19+. GraphPad 
Prism was used to perform one-way ANOVAs and Tukey post hoc 
analyses.
Results: We quantified the percentages and absolute numbers of B 
cells (CD19+), and FoxP3-, CD5- and IL-10-expressing B cells within the 
lymphocyte population of sputum samples (Table 2). We found higher 
percentages, but not absolute numbers, of B cells in AA compared to 
ANA and HC (p < 0.05, Table 2). Although we were able to detect Bregs 
in the airways, the percentages and absolute numbers were similar 
between groups.
Conclusions: The proportion of CD19+ B cells is higher in the airways 
of AA compared to ANA and HC. Bregs are rare cells in the airways; 
although there were no distinct differences in the levels of Bregs, it is 
important to study the function of these cells in order to learn the 
roles they play in suppressing inflammation in the airways of allergic 
asthmatics.
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Background: IgE is critical for allergen-mediated inflammation. IgE is 
expressed by memory B cells (MBC) and plasmablast (PPC) intermedi-
ates, which differentiate into IgE-producing plasma cells (PC). Allergen 
exposure has been shown to increase IgE levels in the airways of aller-
gic asthmatics; however, B cell subsets expressing and producing IgE 
in the airways has yet to be studied.
Methods: Allergic asthmatics (AA), allergic non-asthmatics (ANA) and 
healthy controls (HC) were recruited to donate blood and sputum 
samples. Peripheral blood mononuclear cells (PBMCs) were separated 
using density gradient centrifugation, and stained with CD19, CD27, 
CD38, CD45, CD138, IgG and IgE antibodies with appropriate isotype 
controls. Sputum was induced by inhalation of 3, 4 and 5  % hyper-
tonic saline, and sputum cells were isolated and stained with CD19, 
CD45, IgE and IgG. Cells were acquired using a Becton–Dickinson LSRII 
flow cytometer, analyzed using FlowJo and data were expressed as 
mean ± SEM. Lymphocytes were defined as SSClowCD45+, and B cells 
were defined as SSClowCD45+CD19+. GraphPad Prism was used to 
perform one-way ANOVAs and Tukey post hoc analyses.
Results: Circulating levels of B cells and IgE-expressing B cell sub-
sets, including MBCs (CD27+CD38−), PPCs (CD27+CD38+) and PCs 
(CD38+CD138+) were similar in percentages and absolute numbers 
between AA, ANA and NC. In contrast, the level of IgE-expressing B 
Table 1 Etiology of SCID in patients diagnosed prior to or after initiation of NBS




ADA deficiency 6 4
X‑linked γc chain deficiency 3 1
RAG1 deficiency 2 0
JAK3 deficiency 2 0
CD3δ deficiency 1 0
Cartilage hair hypoplasia 1 0
IL7Rα deficiency 1 0
ZAP70 deficiency 1 0
CORONIN 1A deficiency 1 0
Unknown etiology 3 1
Total 21 6
Table 2 Comparing the percentages and absolute numbers of regulatory B cells 
in the airways of allergic asthmatics, allergic non-asthmatics and healthy controls











1.5 ± 0.3* 2.8 ± 0.3 2.3 ± 0.5
CD19+/SSClowCD45+ 
(%)
13.4 ± 2.0* 6.6 ± 1.5 4.4 ± 1.0
CD19+/CD45 + (%) 0.19 ± 0.04 0.19 ± 0.05 0.08 ± 0.01
CD19+ (×106 cells/g 
of sputum)
0.007 ± 0.002 0.011 ± 0.004 0.002 ± 0.0009
CD19+FoxP3+/
SSClowCD45+ (%)
1.8 ± 0.5 0.6 ± 0.2 0.6 ± 0.3
CD19+FoxP3+/
CD45+ (%)
0.02 ± 0.007 0.02 ± 0.004 0.01 ± 0.008
CD19+FoxP3+ (×106 
cells/g of sputum) 
(%)
0.0006 ± 0.0001 0.0007 ± 0.0001 0.0006 ± 0.0004
CD19+FoxP3+CD5+/
SSClowCD45+ (%)
1.0 ± 0.3 0.4 ± 0.2 0.3 ± 0.1
CD19+FoxP3+CD5+/
CD45+ (%)
0.016 ± 0.009 0.010 ± 0.004 0.005 ± 0.002
CD19+FoxP3+CD5+ 
(×106 cells/g of 
sputum)
0.0004 ± 0.00018 0.0005 ± 0.00017 0.0002 ± 0.00009
CD19+FoxP3+IL‑10+/
SSClowCD45+ (%)
0.35 ± 0.10 0.16 ± 0.07 0.05 ± 0.02
CD19+FoxP3+IL‑10+/
CD45+ (%)
0.005 ± 0.0023 0.004 ± 0.0019 0.001 ± 0.0006
CD19+FoxP3+IL‑10+ 
(×106 cells/g of 
sputum)
0.00013 ± 0.00005 0.00018 ± 0.00007 0.00004 ± 0.00003
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cells in sputum was higher in AA compared to ANA and HC, and this 
was evident when cells were expressed as percentages or as absolute 
numbers (p < 0.05, Table 3).
Conclusions: Compared to allergic non-asthmatic subjects and 
healthy controls, subjects with allergic asthma demonstrated higher 
levels of IgE-expressing B cells in their airways, but not blood. This 
suggests localization of IgE-expressing B cells in the airways of aller-
gic asthmatics, where local production of IgE in the airways may be 
important in the pathogenesis of allergic asthma.
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Background: Primary immunodeficiency disorder (PID) refers to a het-
erogeneous group of disorders characterized by poor or absent func-
tion in one or more components of the immune system. More than 
250 different disorders have been identified to date, with new disor-
ders continually being recognized [1].Treatment in PID patients has 
reduced the mortality and morbidity. Thus, such patients often sur-
vive into adulthood. [2, 3]Although it is likely that more women with 
PID will wish to become pregnant in the future, only a few such cases 
have been reported to date. In this article PID pregnant cases and their 
management has been evaluated.
Methods: The PID cases that became pregnant have evaluated and 
followed in PID clinic, Isfahan University of Medical sciences between 
1997 and 2014. Depend on variety of immunodeficiency, supportive 
and definitive treatment has been done for pregnant patients.
Result: Two patients had pregnancy and were followed and managed. 
A CGD patient with history of recurrent infections such as empyema, 
pneumonia, TB lymphadenitis, cutaneous abscess, mouth ulcer and 
gingivitis whose pregnancy course was uneventful. After normal vagi-
nal delivery, she faced to severe low back pain, sacral fungal osteomy-
elitis and granulomatous lesion all over her uterus and liver who has 
been treated with antifungal and interferon gamma.
Another PID case with CVID and history of upper and lower respiratory 
tract infections and thrombocytopenia who has been managed dur-
ing her pregnancy period and delivery for severe thrombocytopenia 
by higher dose of IVIG and even platelet infusion during her cesarean 
section.
Conclusion: The treatment of PIDs is complex and generally requires 
both supportive and definitive strategies. The pregnancy potentially 
is high risk and immune regulation switch may provide more compli-
cation and disorders during pregnancy. According to the type of PID, 
management and treatment of PID patients could be different and 
future researchers in this area have to be done.
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In Canada intravenous immune globulin (IVIg) products are licensed 
for eight disease indications. Although individual IVIg products are 
not approved for the same indications, Canadian hospitals stock a mix 
of IVIgs leading to their generic use. IVIG products are used for anti-
body replacement therapy and in many autoimmune diseases. First 
approved in Germany in 1995, Octagam® products have been in clini-
cal use for over 20  years in 80 countries. In Canada, Octagam® 10  % 
has been available since 2013. Here we report the routine clinical use 
of Octagam® 10 % across three Canadian institutions, and compare its 
use to other IVIg products licensed in Canada.
A total of 135 patients were treated with Octagam® 10 % for 28 differ-
ent conditions represented by five distinct indication groups: immu-
nology (43  %), hematology (28  %), neurology (17  %), rheumatology 
(5  %), and infectious disease (3  %). Ontario Regional Blood Coordi-
nating Network (ORBCoN) recently published an audit of the routine 
clinical use of IVIg products across Ontario [1]. The audit included 
2246 patients over a 3-month period representing 120 indications. The 
audit captured labeled versus unlabeled utilization. Labeled indica-
tions referred to those that were approved for use by Health Canada 
for at least one IVIg product. The off-label utilization was categorized 
as off-label and potentially indicated, or off-label and not indicated. 
Applying the same criteria set forth in the ORBCoN audit, each of the 
indications identified in this study were similarly classified (Fig. 1).
The results of this retrospective chart review indicate that Octagam® 
10 % is prescribed to Canadian patients similar to other IVIg products, 
with 85 % of the utilization deemed appropriate based on current IVIg 
Table 3 Comparing the percentages and  absolute numbers of  IgE-expressing 
B cells in  the airways and  blood of  allergic asthmatics, allergic non-asthmatics 
and healthy controls
* p < 0.05 compared across subject groups









46.2 ± 3.9 38.3 ± 4.6 50.5 ± 5.1
CD19+/
SSClowCD45+ (%)
11.4 ± 1.0 13.2 ± 0.9 8.6 ± 1.3
CD19+/CD45+ (%) 6.0 ± 0.5 4.4 ± 0.6 4.4 ± 0.8
CD19+ (×106 cells/
mL of blood)
0.38 ± 0.07 0.26 ± 0.04 0.31 ± 0.06
CD19+IgE+/
SSClowCD45+ (%)
0.24 ± 0.05 0.13 ± 0.03 0.27 ± 0.15
CD19+IgE+/CD45+ 
(%)
0.15 ± 0.04 0.06 ± 0.02 0.12 ± 0.06
CD19+IgE+ (×106 
cells/mL of blood)
0.010 ± 0.004 0.004 ± 0.001 0.007 ± 0.003









1.6 ± 0.4 2.0 ± 0.8 1.9 ± 0.4
CD19+/SSClowCD4+ 
(%)
11.8 ± 2.0* 5.7 ± 1.0 4.6 ± 0.6
CD19+/CD45+ (%) 0.18 ± 0.04 0.11 ± 0.03 0.08 ± 0.02
CD19+ (×106 
cells/g of sputum)
0.008 ± 0.002 0.005 ± 0.003 0.002 ± 0.0003
CD19+IgE+/
SSClowCD45+ (%)
3.5 ± 1.0* 0.4 ± 0.1 0.2 ± 0.1
CD19+IgE+/CD45+ 
(%)
0.048 ± 0.011* 0.007 ± 0.002 0.004 ± 0.002
CD19+IgE+ (×106 
cells/g of sputum
0.0020 ± 0.00063* 0.0003 ± 0.00009 0.0001 ± 0.00004
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guidelines [2–4]. Although adverse reactions and efficacy data was 
not reported, the acceptance of its use suggests Octagam® 10 % has a 
comparable safety and efficacy profile to other IVIg products.
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elevations and bilateral ischemic stroke
Michael N. Fein1, Jean‑Philippe Pelletier2
1Department of Clinical Immunology and Allergy, McGill University, 
Montreal, QC, H3G 1A4, Canada, 2Department of Cardiology, McGill 
University, Montreal, QC, H3G 1A4, Canada
Correspondence: Michael N. Fein ‑ Michael.fein@mail.mcgill.ca  
Allergy, Asthma and Clinical Immunology 2016, 12(Suppl 1):A10
Background: Kounis syndrome is a rare but increasingly recognized 
clinical entity whereby anaphylactic or anaphylactoid reactions 
provoke coronary artery spasm that may lead to acute myocardial 
infarction. The pathogenesis is thought to be secondary to mast cell 
activation-degranulation [1]. A “Kounis-like” syndrome has been 
described in two patients with mast cell activation disorders present-
ing with neurologic symptoms yet no evidence of stroke on extensive 
imaging [2].
Case presentation: A 62-year-old male with a history of dyslipidemia 
and hypothyroidism presented with a three-day history of nausea, 
vomiting, fevers, and abdominal pain. There were no complaints of 
chest pain or shortness of breath. On exam he was vitally well but 
had significant left lower quadrant tenderness. His initial blood work 
revealed a leukocytosis of 12.3  ×  10^9/L, a C-reactive protein of 
78 mg/L, and a lactate of 0.9 mmol/L.
During an abdominal computerized tomography (CT) scan with con-
trast, a code blue was called when the patient became hypotensive, 
cyanotic, and lost consciousness. He was intubated and an electro-
cardiogram (ECG) revealed ST elevations in leads II, III, and aVF. A new 
urticarial rash was now present on his abdomen. He was treated with 
intravenous fluids, steroids, and anti-histamines with rapid recov-
ery of his blood pressure. Twenty minutes later a repeat ECG showed 
resolution of the ST elevations; however the troponin level did rise to 
4.43 μg/L. Off sedation, the patient had decreased level of conscious-
ness. A head CT revealed multiple hypo-densities in both cerebral 
hemispheres consistent with cortical and subcortical infarctions in the 
middle cerebral artery territories, thought to be secondary to hypo-
perfusion and cerebral vasospasm.
Conclusion: Kounis syndrome has been associated with a wide 
range of medical conditions, drugs, and environmental exposures. 
We describe the first case of Kounis syndrome secondary to contrast 
media with evidence of coronary vasospasm and bilateral ischemic 
stroke.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Bumble bee allergy is an uncommon cause of Hyme-
noptera venom allergy. Studies have suggested a variable degree of 
immunological cross reactivity between bumble bee and honeybee 
venoms [1]. Bumble bee venom is not available for skin testing in 
Canada.Treating bumble bee allergic patients with honeybee venom 
immunotherapy has been described in the literature [2]. We present 
a case of unsuccessful honey bee immunotherapy in a patient with 
a previous anaphylactic reaction to eastern North American bumble 
bee, Bombus impatiens.
Case presentation: A 32 year old laboratory worker with bumble bees 
had a number of stings over years without reaction. In 2009 he had 
three stings within a few months and developed hypotension, gener-
alized urticaria and wheezing immediately after the third sting. Serum 
IgE levels were markedly elevated for both honey bee and bumble bee 
and he was commenced on honey bee immunotherapy at another 
centre, being maintained on 100  mcg monthly injections for 5  years 
with total compliance. He was not stung over this period. On subse-
quent evaluation he was negative to intradermal testing (0.02  mL) 
with honey bee venom at 1  mcg/mL. A sting challenge to western 
bumble bee (Bombus occidentalis) was done and the patient devel-
oped immediate anaphylaxis symptoms and required treatment with 
epinephrine and antihistamine.
Conclusions: Without access to IgE testing to specific antigens 
contained in various Apidae species, cross-reactivity canntot be 
determined. Immunotheapy with honey bee venom did not protect 
our patient with bumble bee allergy. Bumble bee venom immuno-
therapy has been reported in Europe but European species vary 
significantly from North American species. Our experience sug-
gest significant similarity in allergen content between eastern and 
western bumble bee venoms. With incresing use of bumble bees in 
agriculture, allergic reactions to stings may become more preva-
lent and access to venoms for testing and immunotherapy more 
important.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
Fig. 1 Comparison of the ORBCoN audit findings for IVIg utilization in 
Ontario to Octagam® 10 % utilization across three Canadian Institu‑
tions highlighting labeled, off‑label and potentially indicated, versus 
off‑label and not indicated usage
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Case report: We report a 7-year-old patient with persistant and refrac-
tory auto-immune complications post-hematological stem cell trans-
plantation (HSCT). He was diagnosed at 3 years of age with a leaky SCID 
(homozygous mutations of RAG1) after several auto-immune complica-
tions and repeated infections. He underwent a mismatched umbilical 
cord blood transplantation (5/6) at 40 months with a conditioning regi-
men of Busulfan, Cyclophosphamide and rabbit ATG. His hematological 
reconstitution was good and he was platelet transfusion-free by day 59 
post-HSCT. Chimerism stayed 100 % donor from day 100 post-HSCT.
He presented severe acute and chronic GvHD adequately controlled 
with heavy immunosuppression until 2 years post HSCT. Two and half 
years post-HSCT, he presented with profound peripheral pancytope-
nia. As this pancytopenia was resistant to Prednisone, immunoglobu-
lins and rituximab, he received two injections of Alemtuzumab. While 
red and white blood cells recovered completely, he presented a per-
sistant and refractory immune thrombopenia (ITP) despite treatment 
with prednisone, sirolimus, Rituximab, and two courses of bortezomib. 
A splenectomy was performed with transient efficacy, and romi-
plostim was added to his treatment shortly after.
Concurrently, our patient had very poor immune reconstitution. His 
CD4+T lymphocytes stayed inferior to 200/µl and the emigrant thymic 
naive T cells (CD45RA+CD31+/CD4 cells) were nonexistent. As the 
thymic function seemed to be absent, thymic transplantation was 
discussed. However, with the combination of splenectomy and romi-
plostim as platelet-enhancing therapies, we were able to progressively 
wean prednisone therapy down to a minimal dose of 0.3 mg/kg/day 
with subsequent restoration of thymic function, as shown by uptrend-
ing of CD4+ T lymphocytes and emigrant thymic naive T cells, with lat-
est values of 561/µl and 38 % respectively.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Acquired angioedema is an acquired form of C1 defi-
ciency, where inappropriate bradykinin release can result in skin 
swelling (face and limbs), severe abdominal pain from gastrointesti-
nal mucosal edema and life-threatening upper airway swelling. It has 
been reported in patients with lymphoproliferative disorders. Autoan-
tibodies to C1 inhibitor are present in many of these individuals.
Clinical presentation: Three cases of acquired angioedema are pre-
sented. All three individuals presented over several years with recur-
rent episodes of angioedema and eventually, required ICU admission 
and intubation for airway angioedema. Their lab work demonstrated 
low C4 and C1 inhibitor levels. Given later onset of symptoms and lack 
of family history, they were diagnosed with acquired angioedema. The 
C1q assay was not readily available to confirm the diagnoses.
Case 1, a 76 year old female, had an abnormal peripheral smear, SPEP 
and bone marrow aspirate suggestive her angioedema was secondary 
to a lymphoproliferative process. Case 2, a 77 year old male later devel-
oped colon cancer but his angioedema did not improve with cancer 
treatment, so the two were felt to be unrelated. Case 3, currently a 
56 year old male presented in his early 50s. He underwent gene testing 
for hereditary angioedema which was negative. His laboratory tests 
revealed a small monoclonal band on serum protein electrophoresis.
Management and outcomes: The first two patients were treated with 
danazol prophylaxis. One case had fluctuating levels of C1inh and C4 
that did not correlate with danazol dosage or symptoms. Danazol for 
both cases was titrated to symptoms and maintained at an average dose 
of 200 mg per day. The third case had limited clinical response to various 
doses of danazol and initially required scheduled C1 inhibitor replace-
ment. Eventually, he was treated with tranexamic acid for prophylaxis. 
He has been well controlled with tranexamic acid 1500 mg TID.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: There are limited reports linking the dipeptidyl pepti-
dase-IV (DPP-IV) inhibitor sitagliptin with upper airway angioedema. 
Most reports thus far suggest an interaction with the concurrent use of 
an angiotensin II receptor blocker (ARB) or an angiotensin-converting-
enzyme (ACE) inhibitor. The proposed mechanism is shared inhibition 
of the bradykinin degradation pathway by ACE or DPP-IV inhibitor, or 
increased effect of bradykinin while on ARB.
Case: In March 2015, a 100 pack year former smoker was referred to 
our Adverse Reactions Clinic for recurrent episodes of lip, tongue, and 
throat swelling. These episodes occurred 3–4 times a month for sev-
eral years, with numerous emergency department visits. Our patient 
had been on prednisone 5 mg daily for several years to manage these 
episodes, increasing to 40 mg during an exacerbation. They previously 
had angioedema while taking an ACE inhibitor and possibly following 
aspirin. They also had seasonal allergies, a rash with amoxicillin, and 
GI upset with glyburide. They managed their diabetes with insulin. 
Their other medications included sitagliptin/metformin (Janumet®), 
atorvastatin, hydrochlorothiazide, furosemide, diltiazem, cetirizine, 
domperidone, ezetimibe, levothyroxine, pantoprazole, ranitidine, vita-
min D, ferrous fumarate, B12 injections, docusate, and the following as 
needed: epinephrine autoinjector, nitroglycerin, senekot.
Investigations: Previous investigations for hereditary angioedema 
and systemic mastocytosis negative. CRP 10.2  mg/mL (reference 
range <5.0 mg/L), IgE 15 (<165 KIU/L), and Vitamin D 62 nmol/L (>75 
optimal). Routine bloodwork, immunoglobulins, autoimmune screen, 
C3, C4, C1 esterase inhibitor (q/f ), and tryptase otherwise normal each 
time repeated between 2011–2015.
Course: We advised our patient to discontinue sitagliptin and take 
metformin alone. They have had no further emergency department 
visits for angioedema.
Discussion: Sitagliptin, like ACE inhibitors but not to the same extent, 
may prevent the breakdown of bradykinin. ACE inhibitors are also much 
more likely to cause swelling than ARBs. Although ARBs do not inhibit 
the breakdown of bradykinin, they block bradykinin two receptors and 
make more available to cause swelling. It is thus possible that sitagliptin 
played a role in this patient’s recurrent episodes of angioedema, espe-
cially given the onset of the symptoms after the initiation of the drug 
ten years ago, the disappearance of symptoms with its discontinuation, 
and the similar previous problems with ACE inhibitors. Our patient had 
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several risk factors that would increase her risk of angioedema while on 
ACE inhibitors (and potentially DPP-IV inhibitors). Generally, risk factors 
associated with ACE inhibitor-induced angioedema include previous or 
current smoking, female gender, seasonal allergies, and “African Ameri-
can race”, while having diabetes is protective (as reported in the Oma-
patrilat Cardiovascular Treatment versus Enalapril [OCTAVE] study). Her 
presentation was typical of bradykinin-dependent angioedema, namely, 
swelling lasting several days, without pruritus or urticaria, and being 
somewhat refractory to corticosteroids.
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Background: Subcorneal pustular dermatosis (SCPD) is a rare benign 
chronic inflammatory skin disorder of unknown etiology. First described 
by Sneddon and Wilkinson in 1956, it is characterized by a relapsing 
course of symmetric subcorneal sterile pustules involving the flexures, 
proximal limbs, and trunk. SCPD is often associated with a benign mono-
clonal IgA gammopathy, which can either precede or follow diagnosis. [1].
Case: A 56-year old Caucasian female presented to our outpatient 
immunology-dermatology clinic with a seven-year relapsing history of 
a mildly pruritic and irritating pustular skin eruption under the arms, 
breasts, and around the groin. Physical examination showed several 
pea-sized flaccid pustules on an erythematous base in the axillae, 
groin, and submammary regions (Fig.  2). The patient was otherwise 
well with no signs of systemic disease.
Investigations: Routine blood work including a complete blood 
count and liver function tests were normal. Serum protein electropho-
resis showed an abnormal IgA monoclonal gammopathy lambda type 
with a value of 4.63 g/l (normal 0.7–3.52 g/l). Histopathology showed a 
sterile subcorneal pustule with inflammatory infiltrate of lymphocytes 
and neutrophils with the absence of acantholysis. Her previous treat-
ments included topical corticosteroids and antibiotics as well as oral 
cephalexin and itraconazole, all with poor response.
Discussion: The main differential diagnosis of SCPD includes pus-
tular psoriasis, pemphigus foliaceus, IgA pemphigus, impetigo, 
dermatitis herpetiformis, and acute generalized exanthematous 
pustulosis. Our patient had been previously treated with antibiotic 
and antifungal agents with poor response for an infectious cause 
of the disease. Clinicians may consider an inflammatory disease in 
their differential when presented with a pustular eruption in the 
interigenous areas.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Allergic bronchopulmonary aspergillosis (ABPA) is a 
challenging respiratory disease with significant morbidity and mor-
tality. Among patients with severe asthma, 10 % have ABPA. Typically 
they have a decline in lung function, positive skin prick reaction to 
Aspergillus, elevated IgE levels, increased Aspergillus fumigatus spe-
cific IgE antibody and central bronchiectasis. Patients often exhibit 
refractory symptoms despite conventional asthma therapy. Long-
term use of high dose inhaled and oral corticosteroids may lead to 
serious adverse effects such as immunosuppression, adrenal insuffi-
ciency, metabolic syndrome, hypokalemia, glaucoma, cataracts, peptic 
ulcers, osteoporosis, avascular necrosis, and psychiatric disturbances. 
Antifungals have many drug interactions and may require therapeu-
tic monitoring. Some studies seem to suggest that omalizumab may 
be a better therapeutic option as there is some evidence demon-
strating efficacy in ABPA and fewer adverse effects than long-term 
corticosteroids.
Methods: A retrospective chart review was performed for ABPA 
patients receiving omalizumab between 2007 and 2015 at our tertiary 
care Allergy and Asthma Clinic and The Ottawa Hospital Chest Clinic. 
Data was collected on demographics, total IgE, aspergillus specific skin 
testing, the use of inhaled and oral corticosteroids, quality of life (QoL) 
questionnaires, and number of asthma exacerbations/hospitalizations.
Results: A total of ten patients were evaluated (59.7 ±  13.9  years, 7 
females and 3 males). Compared to their baseline, the average dose 
of inhaled corticosteroids dropped by 24  % at month 16 and out of 
the three patients who were dependent on oral corticosteroids, there 
was an 89  % decrease in prednisone use by month 16. QoL scores 
improved in relation to baseline. Nine of the subjects that reported 
exacerbations 12 months prior to treatment and none reported exac-
erbations once they started omalizumab.
Fig. 2 Flaccid pustules measuring several millimetres in diameter 
on mildly erythematous skin. The image shows a classic half‑and‑half 
blister in which purulent fluid accumulates in the lower half of the 
blister
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Conclusion: Our retrospective study provides evidence to support 
the fact that omalizumab may be an effective low-risk treatment for 
patients with ABPA. Further prospective studies are required to con-
firm this finding.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Cystic fibrosis (CF) is an autosomal recessive disease 
associated with airway obstruction and chronic lung infections. Aller-
gic bronchopulmonary aspergillosis (ABPA) complicates 7–9  % of CF 
cases. The first-line therapies for treating ABPA are corticosteroids and 
antifungal drugs. Long-term use of corticosteroids may result in very 
serious adverse effects such as immunosuppression, adrenal insuf-
ficiency, and diabetes. Antifungals, mucolytics, pancreatic enzymes 
and bronchodilators are also other treatment modalities. A few studies 
suggest omalizumab may be effective in CF. Here we report a 25-year 
old male CF patient with concomitant ABPA complicated with numer-
ous hospitalizations and steroid side effects who responded well to 
omalizumab.
Methods: A retrospective chart review was performed. Evaluation 
jointly occurred at The Ottawa Hospital’s CF Clinic and a tertiary care 
Allergy and Asthma Clinic in Ottawa.
Results: The patient was diagnosed with CF at 5  months old. This 
patient had a positive skin prick reaction to Aspergillus fumigatus and 
a total serum IgE of 111.7 IU/mL. He developed corticosteroid-induced 
diabetes at age 19. Given his poor health and high IgE levels, a decision 
was made to attempt a trial of omalizumab. After 8 months of omali-
zumab, he successfully weaned off of prednisone. After 18  months, 
the patient no longer required insulin to treat his prednisone-induced 
diabetes. After 20  months, his quality of life improved. During the 
12 months prior to treatment he was hospitalized 8 times. He had only 
one hospitalization since month seven. He was considered for a dou-
ble lung transplant, but after 1 year of treatment, transplantation was 
no longer for consideration because he stopped needing daily home 
oxygen.
Conclusion: Omalizumab had a dramatic steroid sparing effect, 
reduced hospitalizations and O2 requirements in this CF patient 
with ABPA and prednisone-induced diabetes. Further prospec-
tive studies using a larger cohort are necessary to make any clinical 
recommendations.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Hereditary angioedema (HAE) with normal C1-esterase 
inhibitor (C1-INH) is subdivided into factor XII mutation or of unknown 
origin (U-HAE). The diagnosis is based on clinical symptoms of recurrent 
edema (commonly skin swellings, tongue swelling), family history, and 
normal C1-INH quantity and function. U-HAE is presumed when fac-
tor XII mutation testing is negative. Here we present a 65 year old male 
with suspected U-HAE, who has a 30-year personal history of recurrent 
upper airway swelling, family history, and normal C1-INH quantity and 
function. He initially responds to empiric C1-INH. However, he seems 
to have developed resistance to C1-INH, requiring rescue therapy with 
icatibant.
Methods: For each treatment, a log method was used to collect infor-
mation on: attack intensity, anatomical location, number of doses, 
onset of relief, time elapsed until complete resolution. Hospital records 
and patient-reports were collected for each treatment received 
through the emergency department.
Results: This patient was first seen September 2013 for suspected 
HAE. C4 and C1 INH quantities and function were repeatedly normal. 
In October 2013, the patient began IV treatment with CI-INH for the 
first time with good response. In June and October 2014, treatment 
with multiple doses of C1-INH was required to achieve resolution 
of symptoms. In February 2015, despite multiple C1-INH doses, the 
patient was intubated and admitted to ICU for tongue swelling with 
throat involvement, which resolved slowly over 4 days. In April 2015, 
icatibant was used for treatment in the ED when on tongue swelling 
occurred and was unresponsive to C1-INH. Swelling began to subside 
within 1 h of the icatibant administration. Since then, the patient has 
had many documented swellings that have not responded to C1 but 
have responded to icatibant.
Conclusion: Icatibant can be an effective treatment for suspected 
U-HAE when treatment response with intravenous C1 esterase inhibi-
tor is inadequate.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Lactose intolerance affects approximately 20  % of 
Canadians and roughly 70  % of the world’s population, leading to 
symptoms of flatulence and bloating after the ingestion of lactose-
containing foods. Lactose intolerance develops primarily due to the 
absence of the enzyme lactase and can occur in childhood or adult-
hood. Treatment involves ingestion of commercially-available lactase 
enzyme preparations often produced by Aspergillus bacteria [1, 2]. 
Although anaphylactic reactions involving IgE mediated hypersensi-
tivity have been reported for a number of foods, this case report repre-
sents the first documented evidence of anaphylaxis after exposure to 
supplemental lactase enzyme preparation.
Case report: A 38  year old white female teacher presented with a 
history of adult-onset lactose intolerance and a suspected allergy to 
lactase tablets after an episode of bilateral orbital swelling, shortness 
of breath, and throat constriction that responded to diphenhydramine. 
The patient’s past medical history included oral allergy syndrome and 
medication-controlled asthma. She handled lactase tablets for years 
due to her children being lactose intolerant but only recently began 
using the tablets herself. Physical examination was benign, and skin 
prick testing to a slurry of the lactase tablet revealed a strongly posi-
tive reaction wheal size of 10  mm and flare of 60  mm with normal 
controls (Fig. 3). The patient required cetirizine treatment in clinic. Skin 
testing was performed with individual ingredients of the lactase tablet 
provided by the manufacturer and Aspergillus niger, a common bac-
teria used in lactase preparations. Only concentrated lactase enzyme 
elicited a positive response. Avoidance of lactase tablets was advised 
and the patient was educated in the use of injectable epinephrine.
Conclusion: This is the first documented case report of an anaphy-
lactic reaction to lactase enzyme. The patient experienced systemic 
symptoms including shortness of breath and orbital swelling, reinforc-
ing the importance of education and avoidance of triggers in these 
rare circumstances.
Disclosures: None.
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Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Primary immune deficiency (PID) is a major risk factor 
for the development of malignancy in both the pediatric and adult 
patient population. It is a major cause of morbidity and mortality, com-
ing second only after infection as the leading cause of death. To date, 
lymphoreticular malignancies are cited as the most common type of 
malignancy known to affect people with PID. Little is known about the 
risk of solid tumor malignancies in this population.
Methods: A literature review and a retrospective chart review of 400 
adult patients at a local private practice was undertaken. Patients were 
selected if they both met a diagnosis of primary immune deficiency 
and solid tumor malignancy. Solid tumor malignancy was defined as a 
malignancy that was neither lymphoma nor leukemia.
Results: Two patients met the criteria of PID and solid tumor malig-
nancy. The first was a male with X-linked agammaglobulinemia (XLA) 
who developed colorectal cancer and the other patient was a female 
with Common Variable Immune Deficiency (CVID) who was diagnosed 
with pancreatic cancer.
Conclusion: There are only a few studies in the literature regarding 
the incidence of solid tumor malignancies and PID. These two cases 
add additional evidence that patients with PID may not only be at risk 
for lymphoproliferative tumors but perhaps of solid tumors as well. 
The diagnosis of PID should alert the clinician to this potential rela-
tionship and ensure patients with PID undergo age appropriate pri-
mary prevention strategies. Additional studies are required to validate 
these conclusions.
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Background: Type II HAE is characterized by functional deficit in C1 
inhibitor (C1 INH). C1 INH function can be assessed by radial immu-
nodiffusion (RID), ELISA or a chromogenic assay [1]. We present our 
institution’s experience with a type II HAE patient, whose disease was 
initially undetected by radial immunodiffusion.
Case presentation: A 62-year-old female was referred to the Clinical 
Immunology Clinic, McMaster University for assessment of type II HAE. 
This diagnosis was made two decades prior when she had recurrent 
abdominal pain and a functional C1 INH deficit detected at a US labo-
ratory. She had no history of facial, extremity or airway angioedema. 
She was previously managed with danazol prophylaxis, which was 
discontinued 15 years prior, and had never required C1 INH infusions. 
There was no family history of HAE. Co-morbidities included allergic 
rhinitis.
Seven months after consultation, while travelling abroad, she experi-
enced a typical HAE flare with facial and airway swelling. She was man-
aged effectively with repeated frozen plasma transfusions. Danazol 
prophylaxis was restarted. Upon return to Canada, she had three addi-
tional flares, managed with C1 INH infusions or icatibant.
Her HAE diagnosis was re-evaluated repeatedly (Table  4). C4 levels 
were consistently low while C1 INH levels were high. Functional assay 
was normal twice, abnormal once and then normal again, as measured 
by radial immunodiffusion at the Clinical Chemistry and Immunology 
Laboratory, Hamilton Health Sciences. For her most recent evaluation, 
C1 INH function was concurrently measured by the chromogenic assay 
at CHU Sainte-Justine, Montreal, QC and found to be low.
Conclusions: A recent paper [1] suggests the chromogenic assay 
is more sensitive for diagnosing C1 INH dysfunction. This case 
Fig. 3 Skin test response to lactase tablet allergen (brand name 
Lacteese) applied to patient’s forearm
Table 4 Patient results
Date C4 comple‑
ment (g/L)
C1 INH level 
(g/L)
C1 INH  
function (RID)
C1 INH function 
(chromogenic 
assay) (U/mL)
May 2014 0.11 (low) 0.67 (high) Normal
June 2014 0.11 (low) 0.81 (high) Normal
March 2015 0.11 (low) 0.61 (high) Abnormal
April 2015 0.11 (low) 0.56 (high) Normal 0.08 (low)
Page 10 of 28Allergy Asthma Clin Immunol 2016, 12(Suppl 1):22
demonstrates radial immunodiffusion’s inaccuracy in diagnosis of a 
patient with type II HAE. We suggest this method be replaced by the 
chromogenic assay which detected the diagnosis in our patient.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: An estimated 2.5 million Canadians (approximately 7  %) 
report living with at least one food allergy. Some experts suggest this 
number is increasing. Epinephrine use and emergency medical services 
are recommended at the first sign of allergic reactions or anaphylaxis, yet 
little is known about the utilization of these resources for allergies in Can-
ada. This study examines emergency department (ED) visits for anaphy-
laxis and allergic reactions and epinephrine auto-injector prescriptions.
Methods: Using data from CIHI’s National Ambulatory Care Report-
ing System, this analysis examines unscheduled ED visits that occurred 
between 2006/07 and 2013/14 with a diagnosis of anaphylaxis or aller-
gic reaction. In addition, claims for epinephrine auto-injectors were esti-
mated between 2006/07 and 2013/14 using data from the National Drug 
Utilization Information System. The analysis describes the patients who 
use the ED for anaphylaxis or allergic reaction and looks at trends over 
time in ED use as well as in prescriptions for epinephrine auto-injectors.
Results: About 1  % of total ED visits were for anaphylaxis or allergic 
reaction. Children and residents of rural areas were over-represented. 
Most visits occurred in the summer months. Since 2006–07, the rate 
of all allergy-related ED visits increased by 6 %, with increases particu-
larly high for children under 18 (29 %) and for anaphylaxis-specific vis-
its (80  %). At the same time, epinephrine auto-injector prescriptions 
increased by 64 %, again particularly among children.
Conclusions: While overall anaphylaxis and allergy rates remained sta-
ble at 1 %, the proportion of visits specifically for anaphylaxis increased 
significantly over time. In addition, an increased number of children 
are receiving prescriptions for epinephrine auto-injectors. Given the 
small increase in overall allergy-related visits, this may reflect a grow-
ing awareness of allergies in Canada and changes in coding practices. 
ED visits remain uncommon and rates of epinephrine auto-injector pre-
scriptions are well below the estimated 7 % of Canadians with allergies.
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Background: The role of gene-environment interactions in the patho-
genesis of food allergy is currently unknown.
Twins provide an invaluable model for genetic studies, allowing the 
separation of genetic from environmental factors. This study aims to 
compare the proband concordance for food allergy in monozygotic 
(MZ) and dizygotic (DZ) twins.
Methods: Twins, where at least one member of the pair had a food 
allergy, were recruited from: Anaphylaxis Canada, Multiple Births 
Canada and the allergy clinic at the Montreal Children’s Hospital. Food 
allergy was diagnosed based on a convincing history of food- induced 
allergy in the presence of a positive skin prick test, or an IgE level of 
at least 0.35  kU/L as well as physician’s report of food allergy. The 
proband concordance [(twice number concordant pairs)/(twice num-
ber of concordant pairs + number of non-concordant pairs)] was com-
pared in MZ and DZ twins for peanut and tree-nut allergies.
Results: Among four pairs of MZ twins and seven pairs of DZ twins for 
peanut allergy, the concordance rate was 0.0 (95 % CI 0.00, 0.60) and 
0.60 (95  % CI 0.27, 0.86) respectively [difference =  0.6 (95  % CI 0.12, 
1.00)].
Among four pairs of both MZ and DZ twins for cashew/pistachio allergy, 
the concordance rate was 0.40 (95 % CI 0.07, 0.82) and 0.66 (95 % CI 0.24, 
0.94) respectively [difference = 0.26 (95 % CI −0.488, 1.00].
Among one pair of MZ twins and four pairs of DZ twins for pecan/wal-
nut allergy, the concordance rate was 0.0 (95 % CI 0.0, 0.94) and 0.66 
(95  % CI 0.24, 0.94) respectively [difference  =  0.66 (95  % CI −0.29, 
1.00].
Conclusion: The higher concordance rate in DZ twins for peanut 
allergy suggests that non-genetic factors play a major role in the 
pathogenesis of peanut allergy. The small sample size renders our 
comparisons for tree nuts inconclusive. Comparisons for egg, milk, 
shellfish, and fish were not performed due to an insufficient sample.
A24  
Qualifying the diagnostic approach employed by allergists 
when managing patients with self‑diagnosed non‑celiac gluten 
sensitivity (NCGS)
Lee Horgan1, Teresa Pun2
1Department of Postgraduate Medicine, Memorial University 
of Newfoundland, St. John’s, Newfoundland and Labrador, Canada, 
2Uptown Health Centre, Toronto, Ontario, Canada
Correspondence: Lee Horgan ‑ leehorgan@gmail.com Allergy, Asthma 
and Clinical Immunology 2016, 12(Suppl 1):A24
Background: Non-celiac gluten/wheat sensitivity (NCGS) is an emerg-
ing entity in the medical literature and lay press. Characterized by 
nonspecific gastrointestinal symptoms that improve with gluten 
restriction, it often remains a self-reported illness [1]. This population 
represents a common and often challenging clinical encounter for 
practicing allergists.
Method: Canadian allergists were identified using publically avail-
able physician registries maintained by each province’s College of 
Physicians and Surgeons. A letter of information was faxed to eligible 
participants and interested parties were invited to complete a brief, 
semi-structured telephone interview discussing their clinical approach 
to NCGS.
Preliminary Results: A letter of information was faxed to the office of 
55 Canadian allergists. At the time of abstract submission, two inter-
views were completed and three were scheduled for a later date. One 
respondent declined participation. Of the completed interviews, 50 % 
of participants were female with an average participant age of 36 
years and an average time in practice of 27 months. Both respondents 
endorsed routine use of wheat allergy skin testing but varied in their 
use of Celiac Disease serology. One endorsed routine referral to gas-
troenterology for consideration of endoscopy. Follow-up practices also 
varied with one participant endorsing routine follow up at six months 
and the other offering follow-up quite infrequently.
Conclusions: Our desired sample size of 15-20 participants will allow 
us to document the Canadian allergist approach to NCGS. We intend 
to use this data to develop clinical care guidelines for NCGS in collabo-
ration with our Canadian allergist colleagues.
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Background: Food allergy is increasingly common in adults [1]. Barri-
ers to performing food challenges, the gold standard diagnostic test, 
have increased reliance on skin prick test (SPT) and food specific IgE to 
adjunct clinical history in diagnosing food allergy [2]. In adults, litera-
ture is scarce on the rate of agreement between these two tests. The 
objective of this study was to investigate the degree of concordance 
between SPT and specific IgE in patients with suspected food allergy.
Methods: A retrospective chart review was performed on adult 
patients seen in the University of Alberta Allergy Clinic between 
October 2013 and April 2015. Demographic and historical data were 
extracted, along with SPT results and food specific IgE titre. SPT wheal 
size >3 mm and specific IgE titre >0.35 kU/L were considered positive.
The agreement between SPT and specific IgE for individual food aller-
gens was analyzed using Kappa coefficients [3].
Results: In the study period, 260 patients presented with a complaint 
of food reaction. There were 29.6 % males and 70.4 % females with a 
mean age of 38.8  years. Peanuts and tree nuts, followed by shellfish 
and fish were the most commonly suspected allergens. Most frequently 
tested allergens were peanut, hazelnut and almond. Agreement 
between SPT and specific IgE result was moderate for peanut (κ = 0.53, 
N =  87) and poor for both hazelnut (κ =  0.14, N =  60) and almond 
(κ = 0.11, N = 60). Kappa analysis for other food allergens is ongoing.
Conclusion: Initial analysis suggests that agreement between SPT 
and specific IgE for commonly suspected food allergens is not strong. 
This study therefore highlights the central role that clinical history 
must continue to play in the diagnosis of food allergy, and suggests a 
greater role for food challenges in the diagnostic algorithm.
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Background: Hypersensitivity to the staple foods, milk, egg and wheat, 
has been described through childhood. We aimed to describe staple 
food hypersensitivity (sFHS), including symptoms and sensitisation by 
allergen-specific Immunoglobulin E (IgE) in a population-based birth 
cohort of Swedish children born in 1994–96 and followed to 16 years.
Methods: Using questionnaire and clinical data, we defined sFHS by 
2 years of age, between 2–4 years of age and at 16 years of age. Symp-
toms included vomiting, diarrhoea, eczema/rash, itch, angioedema, 
rhinitis and/or asthma after staple food consumption. At 1, 2, 4, and 
16 years, parent-reported doctor’s diagnosis of food allergy was ascer-
tained. In a subgroup, sera obtained at 4 and 16  years were analysed 
for IgE to common food allergens (including staple foods) via fx5®. IgE 
reactivity to any or all staple foods was defined as IgE ≥ 0.35 kUA/l. From 
these data, we created three definitions: A: Symptoms only (N = 2386); 
B: Symptoms + doctor-diagnosed food allergy (N = 2386), and; C: Symp-
toms + IgE reactivity (N = 1493). Persistent sFHS was defined as sFHS by 
2  years of age and/or between 2–4  years, and at 16  years. Descriptive 
statistics were used to establish prevalences and to test for differences.
Results: For definitions A and B, the prevalence of sFHS remained sta-
ble from 2 years, to 2–4 years, but increased significantly to 16 years 
(A: 6.3, 4.9, 7.2 %, respectively, p < 0.001; B: 3.7, 2.4, 6.3 %, respectively, 
p  <  0.001). For definition C, the prevalence of sFHS at 4 and 16  years 
was 4.2 and 2.7 %, respectively (p < 0.04).
All children with persistent sFHS, regardless of definition, had symp-
toms, including more severe symptoms, compared to significantly 
fewer children with the same definition of sFHS at 16 years only (e.g. 
definition A: 83.3 %).
Conclusion: There is a discrepancy in the prevalence and symptoms 
of sFHS by definition. Persistent sFHS is associated with more severe 
symptoms.
Funding: JP is a postdoctoral researcher funded by the Karin and Sten 
Mörtstedt Initiative on Anaphylaxis.
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Background: Our previous work identified gaps in confidence for 
administering epinephrine autoinjectors among parents and children. 
The aim of this study is to further describe the impact of supervised 
autoinjector administration by parents/patients on confidence, knowl-
edge and skill for future treatment of severe allergic reactions.
Methods: Patients aged 2–17 years with confirmed IgE-mediated food 
allergy at BC Children’s Hospital (2013–15) undergoing a physician 
supervised oral food challenge were recruited. A pre-challenge ques-
tionnaire validated by expert panel on patient and caregiver back-
ground information and self-assessed confidence (five point scale) in 
the ability to recognize and treat a severe allergic reaction was com-
pleted by each participant. If an autoinjector was deployed during the 
challenge, a similar questionnaire was administered. Since data was 
not normally distributed, Mann–Whitney U and Wilcoxon signed rank 
tests were used to test differences between groups.
Results: Among caregivers who never previously deployed an 
epinephrine autoinjector, 67/104 (66  %) experienced at least one 
severe allergic reaction within the family, and 25/104 (24  %) had 
experienced three or more severe reactions. Pre-challenge median 
scores for recognition of a severe reaction, confidence in autoinjec-
tor administration, knowledge of technique, and autoinjector skill 
were 4(IQR = 1), 3(IQR = 1), 4(IQR = 2), 3(IQR = 2). Further descrip-
tive statistics are in Table  5. Parents who were health professionals 
perceived themselves to be more confident in all domains (median 
difference of 1 for each, p  <  0.05) compared to non-health profes-
sionals. Post-challenge confidence in autoinjector administration 
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and skill among those receiving epinephrine increased by a median 
of 1 and 2 respectively (p < 0.05).
Conclusions: Although participants described reasonable knowledge 
of recognition and technique, confidence and skill for autoinjector 
use were suboptimal. In those who used the autoinjector during an 
oral challenge, perceived confidence in administration and skill levels 
increased. This suggests potential educational benefit of supervised 
epinephrine self-treatment, since many who have never used an epi-
nephrine autoinjector have experienced severe allergic reactions.
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Background: Cystic fibroses (CF) is an autosomal recessive multisys-
temical disorder that is characterized by a progressive neutrophil-
dominated inflammation of the lungs and their colonization by typical 
bacteria. Patients suffering from CF are very often sensitized to Asper-
gillus fumigatus (Asp fum), an ubiquitously occuring fungus. In some 
cases, this can lead to the disease so called, allergic bronchopulmo-
nary aspergillosis (ABPA).
We aimed to investigate whether local antibodies against Asp fum 
(IgG, IgA, IgE) in the lungs of children and adolescents with CF are 
detectable and if there is a correlation with reduced lung function.
Methods: BALF samples of children with CF (n = 49) and a matched 
control group (n = 12) were obtained by bronchoscopy and clinically 
relevant parameters [lung function, BMI, age, Pseudomonas aeruginosa 
(PA) colonization] were assessed. Asp fum -specific IgE was measured 
in serum using ImmunoCAP and Aspergillus-specific antibodies of dif-
ferent Immunoglobulin subclasses (IgG, IgA, IgE) were quantified in 
BALF using an “in house” ELISA.
Results: Local immunoglobulin production against Asp fum was 
observed in more than 80 % of CF patients compared to the control 
group. Specific AF-BAL IgE and systemic specific IgE did not correlate 
with each other in patients with CF (r = 0.26; p = 0.075). CF-patients 
with Asp fum in BALF had significantly increased Asp fum-IgG and 
Asp fum-IgA as compared to patients with no Asp fum detectable in 
BALF. Patients with Asp fum-IgE in BALF displayed a higher forced vital 
capacity as compared to patients with systemic and local IgE.
Conclusions: We provide evidence for local IgE production to AF in 
patients with CF. Local IgE may precede systemic Asp fum-Ige produc-
tion or even have protective effects.
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Background: Allergy skin prick testing involves introducing a small 
amount of allergen extract percutaneously using pointed devices. The cur-
rent standard of care involves placing a drop of extract (40 μL) on the skin 
and then puncturing the skin through the drop via a prick lancet. Alterna-
tive methods include dipping sterile devices into extract and then pressing 
the device onto the skin. The objective of this study was to determine the 
amount of extract used for four devices at different tube/well fill volumes.
Methods: Duotip-test II®, Unitest PC®, Multi-test II® and Multi-test 
PC®, and Prick Lancetter™ devices were studied. For Duotip-test II®, 
gravimetric volume by weight was determined by weighing one 
device before and after placing into a Dipwell® tray/well contain-
ing 50  % glycerin. Twenty-five volumetric measurements were made 
for each device by dipping 5 devices 5 times and then measuring the 
remaining volume with a pipette. Low (0.3 mL), medium (0.6 mL) and 
high (1.0 mL) fill volumes were studied.
Results: Results are shown in Table 6. Volume depletion depended on 
how much extract was in the tube/wells.
Conclusion: Use of single and multiple test devices, tray and wells 
resulted in significantly more tests per vial (486–1923 tests) than 
the “prick and wipe” device (Prick Lancetter™, 143 tests) which may 
significantly reduce extract costs. A comparison of device sterility, 
reproducibility, speed of application and patient pain requires further 
investigation.
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Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
very commonly used drugs worldwide, constituting the second major 
cause of hypersensitivity reactions after beta lactam antibiotics. The 
study’s aim was to evaluate clinical and demographic data of patients 
referred to our hospital with suspected hypersensitivity to NSAIDs.
Method: All cases with NSAID reaction history admitted to our pediat-
ric allergy department between February 2013–2015 were included in 
our study. Case data was compiled by ENDA questionnaires and face-
to-face interviews with parents. Skin tests and/or oral provocation 
tests (OPT) were performed with NSAIDs according to guidelines, after 
obtaining written informed parental consent.
Results: 50 cases (40 % male, 60 % female; mean age 7.36 ± 4.72 years) 
were included. Two patients (4  %) had asthma, rhinosinusitis, and 
nasal polyps, while six (12 %) had allergic underlying diseases—atopic 
dermatitis/asthma/allergic rhinitis.
The drugs considered to have caused the symptoms were acetami-
nophen in 18 (36 %) cases, ibuprofen in 17 (34 %), acetaminophen and 
ibuprofen in 11 (22 %), acetylsalicylic acid (ASA) in 2 (4 %), naproxen in 
1 (2 %), and acetaminophen, naproxen and ASA in one (2 %).
Table 6 Volume depletion per test for allergy skin test devices
0.3 mL 1.0 mL
µL/test % CV Tests/5 mL µL/test % CV Tests/5 mL
Duotip‑test II®‑
gravimetric
2.89 15.6 1730 9.09 8.3 550
Duotip‑test II®‑
volumetric
2.60 3.8 1923 9.15 0.9 546
Unitest PC®‑gravimetric 10.22 8.4 489 20.10 4.9 249
Unitest PC®‑volumetric 10.28 3.2 486 21.20 0.8 236
Multi‑test II®‑volumetric 7.15 3.3 699 9.92 6.9 504
Multi‑test PC®‑
volumetric
8.02 1.5 623 13.82 3.2 362
Prick Lancetter™‑drop 35 9.4 143 35 143
Table 5 Descriptive statistics for pre-questionnaire variables (n = 128)
%
Health professionals 21 %
English as a first language 70 %
Previous experience using autoinjector—at 
least once
18 % (23)
Most common foods challenged Peanut (30 %), egg (28 %), tree nut (12 %)
Failed challenges 28 % (35) (9 patients required epinephrine)
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Presenting complaints were urticaria in 12 (24 %) cases, angioedema in 
5 (10 %), urticaria and angioedema in 13 (26 %), maculopapular/morbil-
liform rash in 18 (36 %), and anaphylaxis in 2 (4 %). Depending on the 
latency between administration of the NSAID and clinical symptoms, 
reactions were immediate in 31 (62 %) patients, delayed in 19 (38 %).
OPT were performed in 17 cases, reporting immediate reactions with 
NSAIDs, resulting positive in three cases with acetaminophen and two 
cases with ibuprofen. In two delayed reaction to NSAID cases, ibuprofen 
patch testing was performed, followed by OPT, both resulting negative.
Conclusions: Skin and/or challenge tests were performed in 38 % of cases 
reporting reactions to NSAIDs. 26 % confirmed as NSAID hypersensitivity. 
In other cases, infections, food, and additives might cause symptoms.
A31 
Reasons for referral and final diagnoses in a tertiary care pediatric 
allergy clinic
Victoria E. Cook1, Kyla J. Hildebrand1, Elodie Portales‑Casamar1, 
Christopher Mill1, Edmond S. Chan1
1Department of Pediatrics, Division of Allergy and Immunology, 
University of British Columbia, Vancouver, Canada
Correspondence: Victoria E. Cook ‑ Victoria.Cook@cw.bc.ca  
Allergy, Asthma and Clinical Immunology 2016, 12(Suppl 1):A31
Background: With the burden of allergic disease increasing worldwide 
[1], prolonged wait times are a significant concern. Published reviews of 
referral patterns have focused on adult populations and do not report 
final diagnoses [2, 3]. This is the first study that we are aware of to compare 
reasons for referral with final diagnoses from a pediatric allergy clinic.
Methods: A review of first presentations to the BC Children’s Hospital 
Allergy clinic is currently underway. Data on age, gender, referral source, 
reason for referral, and final diagnoses were recorded. Descriptive sta-
tistics were used to characterize reasons for referral and final diagnoses.
Results: Among 68 referrals reviewed to date, 78 % were from general 
practitioners, while 22  % came from specialists. Median patient age 
was 4  years (IQR4), and 51  % were female. Most had a single reason 
for referral (84  %). Table  7 shows referral indications and final diag-
noses. Food allergy was the most common reason for referral (71 %), 
followed by allergic rhinoconjunctivitis (22  %), asthma (10  %), drug 
allergy (7 %), parent request (1 %), and laboratory result (1 %). Multiple 
diagnoses were assigned in 10 %. Food allergy was the most common 
final diagnosis (35 %), followed by allergic rhinoconjunctivitis (24 %), 
asthma (4 %), drug allergy (1 %) and food protein induced enterocol-
itis (1 %). Among those referred for suspected food allergy, only 50 % 
had a final diagnosis of food allergy. Nearly half (44 %) of all referrals 
received a non-allergic diagnosis.
Conclusions: We report a higher proportion of referrals for food 
allergy (71  %) than seen in prior reports from mixed adult/pediatric 
practices (19–24  %) [2, 3]. Only half of the patients referred for food 
allergy received a confirmed diagnosis, suggesting many may not 
have required referral. Greater efforts to educate parents and referring 
physicians about when to truly suspect a food allergy and the pitfalls 
of food allergy testing are warranted.
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Background: Unverified, self-reported penicillin allergy is a common 
clinical problem among hospitalized patients. These patients often 
receive broader spectrum, more expensive, and often inferior antibiot-
ics secondary to their unverified penicillin allergy. The large majority 
of patients with self-reported allergy to penicillin do not have a true 
type-I mediated penicillin allergy and could benefit from de-labelling.
Methods: We conducted a retrospective cohort study of 575 consecu-
tive patients admitted to the internal medicine ward at the Montreal 
General Hospital between April 1st, 2014 and September 9th, 2014. 
Each patient’s electronic chart was reviewed for documentation of 
reported penicillin allergy. For patients with reported penicillin allergy, 
their full chart was reviewed to determine what their documented drug 
reaction was, if they had received antibiotics during their admission, 
the indication for antibiotic use, antibiotics received, and presence or 
absence of inpatient or outpatient allergy consultation for evaluation.
Results: A total of 74 patients out of the 575 total admissions dur-
ing the study period reported a penicillin allergy, with a prevalence 
of 12.9  %. Forty patients (54  %) with an unverified penicillin allergy 
received antibiotics during their hospitalization. The most common 
antibiotics prescribed to these patients were moxifloxacin, ciprofloxa-
cin, ceftriaxone, and vancomycin. The most common allergic reaction 
listed in the electronic medical record was unknown (46 %). Only four 
patients (5.4 %) received inpatient consultation with an allergist and 
all of these patients were thought to have suffered an allergic reac-
tion during their hospitalization. There were zero outpatient referrals 
made for hospitalized patients with a history of unverified penicillin 
allergy.
Conclusion: Referral rates for penicillin allergy evaluation continue to be 
extremely low—5.4 % in our study. Given the potential impact de-label-
ling programs may have on antibiotic utilization and stewardship, educa-
tional programs and de-labelling projects are currently being explored.
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Background: Graded drug challenge is used to determine amoxi-
cillin allergy. However, the risk of future reaction upon subsequent 
treatment in those with a negative challenge is currently unknown. 
We aimed to assess the risk of amoxicillin hypersensitivity upon sub-
sequent use in children referred due to suspected amoxicillin allergy 
who had a negative graded oral challenge.
Methods: All children referred to the Montreal Children’s Hos-
pital for potential antibiotic allergy were recruited for the study 
between March 2013 and 2015. A standardized survey with ques-
tions on treatment, symptoms, and possible associated factors was 
filled out and an oral challenge (10 and 90 % of the oral dose) was 
conducted at the clinic visit. Six months after the challenge and 
every 6 months thereafter, the patients were contacted by phone 
to be asked questions on subsequent antibiotic use and associated 
reactions.
Results: Among 366 patients with a negative oral challenge eligible 
for a follow-up, 250 (68.3  %) patients responded. Of the contacted 
patients, 60 (24.0 %) reported amoxicillin use and 7 [11.7 % (95 % CI 
5.2, 23.2  %)] patients reacted to a subsequent treatment. Amoxicillin 
was primarily used to treat acute otitis media (AOM).
Of those seven patients that did not tolerate the amoxicillin, 57.1  % 
were male with a median age of 0.9 years (IQR 0.5, 3.9) at the time of 
reaction and 2.1 years (IQR 1.8, 5.3) at the time of challenge. Sociode-
mographic characteristics and co-morbidities as well as personal and 
familial history of atopy were similar between respondents and non-
respondents to follow-up and also between those that reacted and 
those that tolerated amoxicillin treatment (Table  8). All subsequent 
reactions presented as hives and 85.7 % (95 % CI 42.0, 99.2 %) devel-
oped in the first 3 days of treatment.
Conclusion: The risk of a subsequent reaction among those with 
a negative challenge is almost 10 %. All reactions were limited to 
the skin, but some of the reported skin reactions may have been 
triggered by viral infections and hence the risk may be an overes-
timate. Clinicians can rely on oral challenges to safely assess true 
allergy among children with suspected skin-related reactions to 
amoxicillin.
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Background: 10 % of people claim to have a penicillin allergy. Verifying 
a penicillin allergy is important because it reduces patient exposure to 
other antibiotics that can be associated with increased patient morbid-
ity and healthcare costs. The aim of this study is to report the validity of 
self-reported penicillin allergies in patients presenting to an allergy clinic.
Methods: Retrospective chart review of 284 patients who presented 
to an allergy clinic between April 2011 to December 2014 for penicillin 
allergy assessment. Patients had undergone skin, intradermal testing 
of penicillin and a 5-day oral dose challenge of amoxicillin. Patients 
whose reactions were negative to skin and intradermal testing went 
on to receive a 5-day oral dose challenge of amoxicillin. Patients with 
history of serum sickness or Steven-Johnson syndrome/TENS were 
excluded from this clinic.
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73.3 (60.1, 83.5) 66.3 (59.0, 72.9) 64.3 (54.8, 72.9) 42.9 (11.8, 79.8)
Characteristics of initial reaction





16.7 (8.7, 29.0) 34.2 (27.6, 41.5) 31.0 (23.0, 40.4)
Between 
1–3 days
51.7 (38.5, 64.6) 52.1 (44.8, 59.4) 44.7 (35.5, 54.3) 28.6 (5.1, 69.7)
Between 
4–7 days
20.0 (11.2, 32.7) 26.1 (20.1, 33.1) 33.3 (25.0, 42.9) 28.6 (5.1, 69.7)
>7 days 21.6 (12.5, 34.5) 14.7 (9.8, 20.4) 15.8 (9.9, 24.1) 28.6 (5.1, 69.7)
After treatment 
ended
3.3 (0.6, 12.5) 4.8 (2.4, 9.2) 2.6 (0.6, 8.1) 14.3 (0.7, 0.6)
Known asthma 8.5 (3.2, 19.4) 15.9 (11.1, 22.0) 16.8 (10.7, 25.3) 14.3 (0.7, 0.6)




43.2 (27.5, 60.4) 26.5 (19.4, 35.0) 29.3 (20.0, 40.5) 50.0 (18.8, 81.2)
Parental history 
of asthma
29.3 (12.4, 41.6) 15.9 (10.3, 23.5) 9.8 (4.6, 18.8) 0
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Results: 8.1  % (23 of 284) of self-reported penicillin allergies were 
found to be truly allergic as determined by either skin test, intradermal 
test or 5-day oral challenge. There were 6 reactions to skin and intra-
dermal testing, and these patients did not go on to receive oral doses 
of amoxicillin. Of those who received the oral challenge, a small num-
ber of patients (5 of 284) reacted within 24 h of ingestion of the first 
dose of amoxicillin. A majority of patients (12 of 284) had a delayed 
reaction with a rash occurring 24 h after initial ingestion penicillin. Of 
the oral challenges, the reactions included 6 with hives and 11 with a 
rash. No oral challenge resulted in cardiopulmonary compromise.
Conclusions: Of those reporting a penicillin allergy, only 8.1  % were 
proven to have a reaction. Of these, the majority had a delayed reac-
tion to penicillin, which typically only involved a rash. There were no 
life-threatening reactions. Penicillin allergy testing can determine 
whether patients should actually be avoiding penicillin.
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Background: Currently there is no consensus on the optimal treatment 
of eosinophilic esophagitis (EoE). One of the options, an elimination diet 
guided by allergy test results, has been shown to be effective to varying 
degrees with greater efficacy in pediatric cohorts [1, 2]. However, results 
in adults have been less promising as higher rates of negative allergy 
tests hinder efforts to guide the diet [3]. This study explores the results 
of allergy-test directed elimination diets in a group of patients (n = 16) 
treated at the Allergy and Immunology Clinic in London, Ontario.
Methods: A retrospective chart review was performed using a data-
base of patients diagnosed with EoE (histology ≥ 15 eo/hpf in esoph-
ageal biopsy) and treated at the Allergy and Immunology Clinic at St. 
Joseph’s Hospital, London, ON. Patients were included in the review 
if they had been prescribed an elimination diet guided by allergy 
testing [skin-prick test (SPT) and/or atopy patch test (APT)], and had 
esophageal biopsies taken ≥ 8 weeks after initiation of the diet.
Pre-treatment eosinophil counts were recorded from peak eosinophil 
counts of the most recent biopsy prior to initiation of the elimination 
diet.
Results: The average age of subjects at diet initiation was 43.75 years 
(see Table  9 for subject demographics). On average, each subject 
eliminated 1.7 foods from their diet. Post-diet biopsies displayed a 
significantly lower level of peak eosinophils/hpf compared to pre-diet 
biopsies on average (37.9 vs. 89.8, p = 0.043; Fig. 4). Three patients had 
post-diet biopsies below the histological threshold of diagnosis for 
EoE (<15 eo/hpf).
Conclusions: This chart review shows that patients undergoing elimi-
nation diets directed by allergy tests have significant histological 
improvement after their diets. It must be noted that this review did 
not control for the effects of confounding treatments such as PPIs and 
corticosteroids, with the latter being of greater concern to histological 
results. Half of the subjects examined (8 out of 16) had been, at some 
time before the post-diet biopsy, prescribed swallowed corticoster-
oids for EoE. However, only 1/4 of steroid-prescribed subjects reported 
using the steroids during the 30-day period immediately prior to their 
post-diet biopsy.
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Background: Foods are a major trigger for eosinophilic esophagi-
tis (EoE) in children; however, the optimal method for identifying the 
causative foods is unclear. We investigated the role of allergy testing in 
a pediatric tertiary centre and its use in identifying causative foods in 
children with biopsy-confirmed EoE.
Methods: A retrospective analysis of all children diagnosed with 
EoE by a pediatric gastroenterologist from January 2004 to Sep-
tember 2014 was completed. All patients met criteria for diagnosis 
defined by symptoms of esophageal dysfunction and biopsy-proven 
eosinophilia with greater than 15 eosinophils per high-power field 
(hpf ).
Results: Ninety-eight (98) children were included (average age 
10.4  years, 77  % male, and 61  % atopic). Presenting symptoms 
included dysphagia (52  %), abdominal pain (38  %), and GERD 
Table 9 Demographics and confounding treatments
a  Considered to use if any prescriptions after EoE diagnosis
b  Only 1/4 of patients prescribed swallowed corticosteroids had used them in the 




Average age at diet initiation, years (range) 43.75 (2–65)
Average # foods eliminated (range) 1.7 (1–3)
Average # days to post‑diet biopsy 192
Positive APT 15/16
Positive SPT 5/16
























Fig. 4 Average esophageal eosinophil level is decreased after 
initiation of elimination diet. Error bars represent standard error used 
in paired t test to compare the pre‑diet and post‑diet averages 
(p = 0.043)
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(35 %). 69 patients were assessed by an allergist, 62 had skin prick 
testing (SPT) to foods; 40 were positive, most commonly to egg, 
soy, peanut and rice. 50 had atopy patch testing (APT); 26 were 
positive, most commonly to chicken, egg, wheat and corn. 46 
patients underwent dietary intervention as part of their manage-
ment, with 27 patients (57 %) reporting symptom improvement. 14 
patients had follow-up endoscopy and nine had documented histo-
logic improvement. With dietary interventions, the average number 
of foods avoided was 2.7.
Conclusions: Approximately half of the EoE patients undergo-
ing dietary modifications based on allergy testing reported symp-
tom improvement. When compared to the Six-Food Elimination 
Diet (SFED), patients avoided on average fewer foods. A staged-
approach using SPT and APT followed by SFED may be an option 
for some patients, with the advantage of potentially avoiding less 
foods. This benefit needs to be balanced against the time required 
for allergy testing. Further studies comparing the feasibility of 
these two dietary approaches in the management of EoE in chil-
dren are needed.
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Background: Cutaneous disease is known to impact psychosocial 
wellbeing. This sentiment is especially true in the chronic inflamma-
tory dermatoses such as atopic dermatitis and idiopathic urticaria. 
Degree of itch plays a role, as do age and socioeconomic status. There 
is poor correlation, nonetheless, between severity and impact of skin 
disease, and physicians are themselves poor at gauging the psychoso-
cial impact of skin problems [1]. We set out to visualize this impact by 
means of a word cloud.
Methods: Participants answered the open-ended question “How has 
your skin affected you (e.g. your mood, self-image, relationships, dis-
comfort)?” Responses were transcribed into the word cloud software 
Wordle [http://www.wordle.net].
Results: Eighty responses were recorded, with a mean age of 44 and a 
mean word count of 20. Twenty-five of 80 participants screened posi-
tive for depression by scoring three or above on the two-item PHQ-2 
tool. Seven of eight participants whose complaints included the atopic 
or allergic screened positive—these included patients with atopic 
dermatitis, idiopathic urticaria, hand eczema, and allergic contact der-
matitis. More frequent phrases were given a proportionally larger size 
in the graphic. Figure 5 visualizes the answers provided by the eight 
atopic and allergic patients.
Conclusions: Clinicians cannot overlook psychosocial wellbeing in skin 
disease. Specialists pressed for time may consider aligning themselves 
with a skin-emotion expert, be it a social worker or psychiatrist [2].
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Background: Sinonasal disease is often diagnosed in patients with 
cystic fibrosis (CF). Some studies suggest that CF patients with nasal 
polyps have less severe pulmonary disease and overall improved sur-
vival. Our study examines factors associated with nasal polyposis in 
pediatric CF patients.
Methods: Cross-sectional study of 26 CF patients (2008–2011). 
Nasal polyps were diagnosed by anterior rhinoscopy. The study 
group (n = 16, 61.5 %): CF patients with nasal polyposis. The com-
parison group (n =  10, 38.5  %): CF patients without nasal polypo-
sis. Clinical/biochemical data were gathered. Pulmonary function 
test, skin prick test, sputum/throat culture, nasal lavage and geno-
type analysis were performed. Minitab (t test, Chi square test) and a 
p value of < 0.05 were used for statistical analysis and significance, 
respectively.
Results: CF patients with nasal polyps are more likely to have Asper-
gillus serum precipitins (50 vs 10  %, p  =  0.02). Positive allergy skin 
prick tests are common (50 vs 70  %, p =  0.29). Atopy to Aspergillus 
fumigatus is most prevalent in the nasal polyposis group (62.5 vs 
42.85  %, p  =  0.29). Other appreciable characteristics of this group 
are: better nutritional status (mean BMI 20.7 vs 18.7 kg/m2, p = 0.06), 
ΔF508 homozygosity (68.7 vs 40  %, p =  0.13), suboptimal vitamin D 
levels in winter (83.3 vs 50 %, p = 0.14) and better pulmonary function 
(mean FEV1 % predicted 82 vs. 78, p = 0.4). Staphylococcus aureus is 
the most common pathogen in the sputum/throat cultures and neu-
trophils are prevalent in all nasal lavage samples, with no difference 
between the groups.
Conclusions: Patients with CF and nasal polyposis may constitute a 
clinical subgroup within the spectrum of the disease. These patients 
appear to have a higher exposure to Aspergillus. This, together with 
the higher prevalence of atopy to Aspergillus, may suggest an associa-
tion with nasal polyposis. Also more likely are: ΔF508/ΔF508 genotype, 
better pulmonary function/nutritional status, and lower vitamin D lev-
els in winter. Our results confirm and complement those of previous 
studies.
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Background: Studies suggest that up to 10  % of children develop 
rashes while on antibiotics for respiratory infections [1]. The majority 
Fig. 5 Word cloud depicting relative quantity of words used in 
response to the question, “How has your skin affected you (e.g. your 
mood, self‑image, relationships, discomfort)?” Only inclusive of partici‑
pants with atopic or allergic skin disease
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are diagnosed without further evaluation and are labelled as allergic 
to the implicated antibiotic. There is sparse data regarding the per-
centage of established macrolide allergy among children who present 
with suspected macrolide hypersensitivity. Furthermore, there are no 
standardized skin tests to confirm the presence of macrolide hyper-
sensitivity [2]. Our objective was to assess the risk of a hypersensitivity 
reaction through the use of a graded oral challenge in patients with a 
suspected macrolide allergy.
Methods: As part of the LAACTAM (β-LActam and other Antibiotics 
allergy in Children: Tests, assessment and Management) study, chil-
dren presenting to the allergy clinic at the Montreal Children’s Hospi-
tal for the assessment of a potential macrolide antibiotic allergy were 
recruited. Data on demographics and reaction characteristics was col-
lected through a standardized questionnaire. Patients underwent a 
graded challenge (10 and 90 % of the dose) of either azithromycin or 
clarithromycin, and were observed for 1 h after the last dose. In addi-
tion, patients were contacted every 12 months to query on potential 
non-immediate reactions or reactions on subsequent use.
Results: Fifty-one subjects with a macrolide allergy were recruited. 
80.4 % (95 % CI 66.5, 89.7 %) had reported a reaction to clarithromycin 
and 19.6 % (95 % CI 10.3, 33.5 %) to azithromycin. The majority of reac-
tions were isolated to the skin and occurred within the first 3 days of 
the antibiotic course (Table 10). Three subjects out of 51 (5.9 % [95 % 
CI 1.5, 17.2  %]) had a positive graded challenge. All three reactions 
were limited to the skin and occurred within the first hour of obser-
vation. No late reactions were documented and none of the patients 
reported repeated use of the culprit macrolide.
Conclusion: The risk of a reaction in children with a history of a mac-
rolide hypersensitivity is low and seems to occur within 1 h of the oral 
challenge. Currently an oral provocation is the best tool in diagnosing 
a macrolide allergy. Larger studies are needed to support these find-
ings and identify risk factors associated with positive challenges.
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Background: Many institutions recommend a stepwise approach to 
intradermal testing for venom allergy [1]. This is costly and uncom-
fortable for the patient. The rational for this approach is the risk of 
potential adverse reactions to testing with the maximal dose alone. 
Strohmeier et  al. [2] recently described the safety of a simultaneous 
approach to testing different venom concentrations, and Yocum has 
previously described the safety of a two-step approach to testing [3]. 
Our objective of this study was to evaluate the safety of a single step 
approach to venom allergy testing.
Methods: We retrospectively reviewed charts of 300 consecutive 
patients with suspected hymenoptera venom allergy based on his-
tory that underwent venom allergy testing in a single allergist’s clinic 
where a single step protocol had been adopted. Charts were reviewed 
for patient characteristics including medications, testing protocol 
used, results of testing, and reported immediate and delayed adverse 
reactions to testing.
Results: All patients underwent testing with an identical single-step 
protocol with an intradermal dose of 0.02  mL of a 1.0  μg/mL con-
centration of each of the five commercially available vespid and bee 
venoms. Patients ranged from 4 to 83 years of age. Only one patient 
reported an adverse reaction to testing, which was delayed until the 
morning following his visit. There were no immediate adverse reac-
tions. This patient was successfully started on venom immunotherapy 
subsequent to his reaction.
Conclusion: A single step venom allergy intradermal testing protocol 
with a 1.0 μg/mL concentration of commercially available extracts is a safe 
option, which, if adopted into practice, would potentially lead to more 
streamlined care for patients and cost savings for the medical system.
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Background: Characterizing reactions and assessing the safety of 
future cephalosporin administration in children is important, given the 
critical role these antibiotics play in the empirical treatment of serious 
infections. Because skin tests to cephalosporins remain to be validated 
[1], we aimed to evaluate the usefulness of oral challenges in assessing 
the risk of future reaction to these drugs.
Methods: Children presenting to drug allergy clinics at the Montreal 
Children’s Hospital during a consecutive 3-year period starting in March 
2012, with a history of suspected hypersensitivity to cephalosporins, 
received graded oral challenges (10 %, followed by the remaining 90 % 
Table 10 Characteristics of macrolide hypersensitivity reactions in children
Age at time of reaction (median, IQR) 1.25 years (0.48, 3.09)
Gender (%)
 Male (95 % CI) 52.9 % (38.6, 66.8)
Symptoms
 Urticaria 62.7 % (48.1, 75.5)
 Generalized pruritus 33.3 % (21.1, 48.0)
 Maculopapular rash 25.5 % (14.8, 39.9)
 Angioedema 15.7 % (7.5, 29.1)
 Gastrointestinal 3.9 % (0.7, 14.6)
 Throat tightness 2.0 % (0.1, 11.8)
 Breathing difficulties 2.0 % (0.1, 11.8)
 Arthritis/arthralgia 2.0 % (0.1, 11.8)
Time of reaction after 1st dose
 After 1–3 days 62.7 % (48.1, 75.5)
 After 4–7 days 21.6 % (11.8, 35.7)
 After >7 days 11.8 % (4.9, 24.6)
 After treatment ended 2.0 % (0.1, 11.8)
Duration of reaction
 1–3 days 80.3 % (66.5, 89.7)
 4–7 days 13.7 % (6.2, 26.8)
 >7 days 5.8 % (1.5, 17.2)
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of the daily dose). We collected data on patient demographic and clini-
cal characteristics using a standardized questionnaire and assessed the 
risk for immediate (within 1 h) and non-immediate reactions.
Results: Of the 56 children (52 % males) evaluated, 45 (80.4 %) had a 
suspected hypersensitivity to cefprozil [95  % CI 67.2, 89.3]. The rest of 
the study participants had a history of suspected reaction to cefixime 
(n = 4), cephalexin (n = 3), cefuroxime (n = 2), cefazolin (n = 1) or cef-
triaxone (n = 1). Most of the initial reactions had been cutaneous, with 
73.1 % of respondents reporting hives [95 % CI 59.5, 83.8], 16.1 % report-
ing maculopapular rash [95  % CI 8.1, 28.8] and 14.3  % angioedema 
[95  % CI 6.8, 26.8]. The majority of the reactions had occurred on first 
exposure to the drug and 1-3 days into the course, at 66.1 % [95 % CI 
52.1, 77.8] and 63.3  % [95  % CI 49.5, 75.9], respectively. 32.1  % of the 
reactions developed 1-8 h after the most recent dose had been taken 
[95 % CI 20.6, 46.1] and 39 % developed more than 8 h after the dose 
[95 % CI 26.8, 79.2]. Following oral challenge, 2 participants developed 
immediate mild (cutaneous) reactions (3.6 %; 95 % CI 0.6, 13.4], both to 
cefprozil. Two participants developed non-immediate mild (cutaneous) 
reactions (one to cefprozil and the other to cephalexin).
Conclusion: The risk of reaction is low in children with a history of sus-
pected hypersensitivity to cephalosporins. Oral challenges appear to 
be safe in this population, and may be the best tool available to diag-
nose cephalosporin hypersensitivity. Larger studies are needed to sup-
port these results.
Reference
1. Joint task force on practice parameters, American academy of allergy, 
asthma, and immunology: drug allergy: an updated practice parameter. 
Ann Allergy Asthma Immunol. 2010;105:259e273.
A42 
Breastfeeding and infant wheeze, atopy and atopic dermatitis: 
findings from the Canadian Healthy Infant Longitudinal 
Development Study
Meghan B. Azad1, Zihang Lu2, Allan B. Becker1, Padmaja Subbarao2, 
Piushkumar J. Mandhane3, Stuart E. Turvey4, Malcolm R. Sears5, the CHILD 
Study Investigators6
1Department of Pediatrics and Child Health, University of Manitoba 
and Children’s Hospital Research Institute of Manitoba, Winnipeg, MB, 
Canada, 2Department of Pediatrics, Hospital for Sick Children, University 
of Toronto, Toronto, ON, Canada, 3Department of Pediatrics, University 
of Alberta, Edmonton, AB, Canada, 4Department of Pediatrics, Child 
and Family Research Institute and British Columbia Children’s Hospital, 
University of British Columbia, Vancouver, BC, Canada, 5Department 
of Medicine, McMaster University, Hamilton, ON, Canada, 6Canadian 
Healthy Infant Longitudinal Development Study
Correspondence: Meghan B. Azad ‑ meghan.azad@umanitoba.ca  
Allergy, Asthma and Clinical Immunology 2016, 12(Suppl 1):A43
Background: The impact of breastfeeding on asthma and allergy 
development is controversial. We aimed to characterize the associa-
tion of breastfeeding with childhood wheeze, atopy and atopic der-
matitis in the first year of life.
Methods: We studied 2587 infants with complete breastfeeding data 
from the Canadian Healthy Infant Longitudinal Development (CHILD) 
birth cohort. Infant diet and wheezing episodes were reported by 
mothers at 3, 6, and 12 months. Atopy was determined by skin testing 
and atopic dermatitis was diagnosed at 12 months. Breastfeeding was 
classified as exclusive (human milk only), partial (supplemented with 
formula, other beverages or solid foods) or none.
Results: Breastfeeding rates were 82 % at 3 months (52 % exclusive, 
30  % partial), 74  % at 6  months (13  % exclusive, 61  % partial), and 
46 % at 12 months (partial). In their first year, 21 % of infants experi-
enced  ≥  1 wheezing episode, 14  % were sensitized to  ≥1 allergen, 
and 12 % were diagnosed with atopic dermatitis. Breastfeeding rates 
were lower among younger mothers, First Nations women, and those 
who smoked or did not have a postsecondary degree. Independent 
of these maternal characteristics, increasing duration and intensity 
of breastfeeding were associated with a reduced risk of wheezing: 
adjusted odds ratio (aOR) 0.97 (95 % CI 0.94–0.99) for each additional 
month of breastfeeding; aOR 0.68 (0.50–0.92) for exclusive versus no 
breastfeeding at 3 months. In contrast, breastfeeding was associated 
with an increased risk of atopy: aOR 1.04 (1.01–1.07) for each addi-
tional month; aOR 1.46 (1.02–2.10) for exclusive versus no breastfeed-
ing. Breastfeeding was not associated with atopic dermatitis.
Conclusions: In the CHILD cohort, increasing duration and intensity of 
breastfeeding are associated with a lower risk of wheeze and a higher 
risk of atopy in the first year of life. Ongoing research will address 
potential confounding by reverse causation, extend analyses through 
early childhood, and evaluate physician-diagnosed asthma and food 
allergy.
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Background: Inflammation is a key mechanism of asthma pathogen-
esis [1]. The bronchial epithelium acts as a barrier involved in innate and 
adaptive immunity through secretion of inflammatory mediators [2]. 
Interleukin (IL) 33 is an alarmin cytokine released by airway epithelial cells 
[3] that has been identified as a gene of susceptibility in asthma in several 
studies [4–6], as well as being a potential severity biomarker of asthma 
[7]. IL33 gene expression was increased in epithelial cells from asthmatic 
individuals [8]. However, less is known about the epigenetic regulation of 
IL33 particularly in severe asthma. In this context, we aimed to character-
ize DNA methylation (DNA-me) and expression signatures of IL33 in epi-
thelial cells obtained from mild and severe asthmatic individuals.
Methods: A total of 21 bronchial epithelial cell (BEC) lines from asth-
matics individuals (mild n =  7; severe n =  4) and control individuals 
(n = 10) were used for DNA and mRNA extraction. DNA-me was meas-
ured by bis-pyrosequencing and mRNA level was assessed by qRT-PCR. 
Student t tests were performed to analyze the association between 
DNA-me and asthma severity (significant for Δβ > 5 % and p > 0.05). 
Pearson correlations were used to analyze the correlation between 
DNA-me and mRNA level.
Results: A hypomethylation for mild and severe BEC groups 
(Δβ  =  22  %, p  =  0.003; Δβ  =  17  %, p  =  0.090 respectively) was 
observed. The DNA-me of IL33 promoter was also negatively correlated 
with mRNA levels (r  =  −0.750, p  =  0.050), suggesting an upregula-
tion of gene expression by DNA-me. The total mRNA level for IL33 was 
increased in BECs from mild and severe asthmatic individuals (fold-
change = 3.4, p = 0.017; foldchange = 4.7, p = 0.060 respectively).
Conclusion: Methylation modifications in IL33 promoter could modu-
late gene expression in epithelial cells of asthmatic individuals. This 
study highlighted the relevance of IL33 as a potential biomarker of 
asthma severity.
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Background: Bronchial epithelial cells play an important role in medi-
ating the response to airway injury and repair through the release of 
chemotactic factors, such as interleukin 8 (IL-8) and antioxidant pro-
duction. These antioxidant mechanisms are particularly important in 
the context of neutrophil-mediated pulmonary disease. Inhalation of 
organic dust (OD) from swine confinement facilities leads to pulmo-
nary neutrophilia, airway hyperresponsiveness and oxidative stress. 
We sought to examine the role of NRF2, a critical transcription factor 
involved in mediating the endogenous antioxidant response, in bron-
chial epithelial cells following OD exposure. We hypothesized that OD 
exposure would increase NRF2 activity and antioxidant production in 
human bronchial epithelial cells.
Methods: A human bronchial epithelial cell line (BEAS-2B) was stimu-
lated for 24 h with 100 µg OD. Supernatant was retained for evaluation 
of IL-8 by ELISA. qPCR was performed for NRF2-dependent and NRF2-
independent antioxidant genes. NRF2 nuclear translocation was quan-
tified at various time points using an NRF2 luciferase reporter assay 
and by immunofluorescence.
Results: OD exposure resulted in an increase of IL-8 release. mRNA 
expression levels of NRF2-dependent antioxidant genes HO-1, NQO1 
and GCLM, but not of NRF2-independent antioxidant genes SOD 
1, and catalase were increased following OD exposure compared 
to control cells. OD exposure induced a time and dose-dependent 
increase in luminescence indicating NRF2 nuclear translocation, a 
result confirmed by quantification of NRF2 nuclear localization by 
immunofluoresence.
Conclusions: OD exposure induces IL-8 release, NRF2 nuclear trans-
location, and upregulation of antioxidant gene expression in BEAS-2B 
cells. These results suggest a dual role for bronchial epithelial cells in 
mediating neutrophil recruitment as the endogenous antioxidant 
response. We demonstrated that the endogenous oxidative properties 
of OD are specific to NRF2 and that NRF2 is a critical mediator of OD-
induced oxidative stress in bronchial epithelial cells.
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Background: Perinatal psychosocial distress, including stressful life 
events, anxiety and depression are risk factors for childhood atopic 
dermatitis (rash) [1]. Maternal psychosocial distress is associated 
with excess prenatal stress hormones [2] and reduction in the qual-
ity of maternal-infant interaction [3], which may affect biomarkers 
of infant immunity such as interleukin (IL) levels and predispose the 
growing child to rash [4, 5]. This study will: (1) describe the association 
between perinatal distress and infant interleukins at 3 months of age, 
(2) describe the association of interleukins and atopic dermatitis (rash), 
and (3) build a best fit model from the identified associations in (1) and 
(2).
Methods: 120 women reported distress levels during pregnancy 
and at 3 months postpartum. Venous blood was collected from their 
3-month-old infants to assess plasma interleukin levels. Maternal-child 
interaction was measured 6  months postpartum with the nursing 
child assessment teaching scale. Presence and number of skin areas 
affected by rash were assessed via parent report at 18 months. Correla-
tion and multiple regression analyses identified the best fit model for 
rash using forward stepwise regression.
Results: Prenatal depression (r  =  −0.23, p  =  0.01) and stressful life 
events pre- and post-natally (r  =  0.27, p  =  0.00) were associated 
with IL2p70. Pre- and post-natal anxiety were associated with IL8 
(r = −0.28, p = 0.02) and IL4 (r = −0.24, p = 0.04). IL10 was associated 
with child skin rash (r = −0.25, p =  0.01) at 18  months. 20  % of the 
variance in childhood rash at 18 months was explained by the model 
(Table 11).
Conclusions: Perinatal distress is associated with elevated infant ILs. 
Demographic variables (maternal age, education), IL10, perinatal 
stressful life events (e.g. separation/divorce, family death) and mater-
nal-infant interaction best predicted skin rash in 18-month-old infants. 
We will now evaluate how maternal-child interaction moderates asso-
ciations between both (1) perinatal distress and (2) immune biomark-
ers, and atopic dermatitis in children at 18 months.
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Table 11 Multiple regression analysis for variables predicting child skin rash
Note IL10 was transformed by taking the square. * P < 0.05
Variables Estimate Standard error P value
Maternal age −0.03 0.01 0.023
Maternal education 0.11 0.06 0.091
IL10 −1.31 0.41 0.002
Perinatal stress −0.12 0.06 0.057
Maternal‑infant interaction quality 0.02 0.01 0.018
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Background: Oral tolerance is a state of unresponsiveness of the 
immune system to food antigens. Failure of tolerance can lead to 
future allergic reactions. Milk allergy, is the most common childhood 
allergy, affecting between 2–7  % of children [1]. Beta-lactoglobulin 
(BLG) is a major allergen in cow’s milk. Several factors, such as trans-
forming growth factor-beta, vitamin A, and soluble toll-like receptors 
(TLRs) that are found in breast milk, are thought to enhance oral tol-
erance toward breastmilk-transferred antigens. In contrast, we have 
shown previously that PAM3CSK4, a TLR2 activator, is able to disrupt 
oral tolerance toward ovalbumin in mice. The variable levels of these 
tolerogenic or sensitizing factors in breast milk or baby formulas might 
be critical to the development of tolerance or allergy. The objective of 
this work was to better understand the impact of these milk factors in 
the development of tolerance toward milk-antigens.
Methods: Models of oral tolerance to cow’s milk, BLG, and ovalbumin 
were established. Oral tolerance was assessed in wild type and TLR2-
deficient mice through analysis of antigen-specific antibody levels 
after a systemic antigen challenge. The development of antigen-spe-
cific Tregs was also assessed.
Results: Oral administration of doses of skim milk (above 1  mg/mL 
protein for 7 days) or BLG induced the development of oral tolerance, 
independently of TLR2. Immunoglobulin-E levels in antigen fed mice 
were 35 % of the control (n = 15). In contrast to ovalbumin, tolerance 
induction to BLG in milk was not altered by the addition of PAM3CSK4. 
Heat-killed Lactobacilli also did not modify milk tolerance. These 
results indicate that immunoregulatory factors in milk modify the 
response to an oral TLR2 activator.
Conclusion: This research could provide important insights into the 
significance of specific milk contents for the development of milk 
and other allergies, potentially informing both allergy prevention and 
treatment strategies.
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Background: The study aimed to evaluate tryptase levels in chil-
dren presenting with anaphylaxis, to examine predictors of elevated 
tryptase (defined as levels ≥11.4 ng/mL), and to compare tryptase lev-
els during and post-anaphylaxis.
Methods: Between April 2011 and September 2014, data were col-
lected on anaphylaxis cases at the Montreal Children’s Hospital Emer-
gency Department. Cases were recruited either prospectively or 
identified retrospectively through chart review. Total tryptase levels 
were measured within 2 h following onset of symptoms. Levels during 
reaction and approximately 10 months after reaction were compared 
using confidence intervals based on paired means using the t distri-
bution. Logistic and linear regression models were fit to estimate the 
associations between tryptase levels and sociodemographic and clini-
cal characteristics of anaphylaxis.
Results: Over a three-year period, 165 children were recruited and 
had serum tryptase levels measured. Among those, the mean tryptase 
level was 7.6 μg/l (SD 6.4) and 32 cases [19.4 % (95 % CI, 13.8, 26.4 %)] 
had elevated tryptase levels. Elevated levels were found more fre-
quently in severe reactions compared to moderate and mild reactions 
(Table 12).
Of the 54 children with post-reaction tryptase levels, the mean 
tryptase level was 8.2 μg/l during reaction and 3.7 μg/l post-reaction; 
yielding a difference of 3.5 (95 % CI 2.96, 3.96). Only severe reactions 
were associated with elevated tryptase levels (≥11.4  μg/l) [OR 7.2 
(95 % CI 2.11, 24.40)]. Factors associated with an increase in tryptase 
levels regardless of previously published thresholds were severe reac-
tions and milk trigger [beta = 10.3 (95 % CI 6.9, 13.7) and 4.3 (95 % CI 
0.5, 8.0)], respectively.
Conclusions: Our study results do not support the role of tryptase as 
a reliable diagnostic biomarker for the diagnosis of anaphylaxis in chil-
dren. Assessing the difference between levels during and post-reac-
tion may improve the diagnostic utility of tryptase, mainly in severe 
reactions or reactions triggered by milk. Future studies are needed to 
evaluate more reliable diagnostic biomarkers.
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Background: Previous studies have demonstrated a link between 
early-life exposure to secondhand tobacco smoke (SHS) and allergen-
specific immunoglobulin E (IgE) mediated sensitization to food aller-
gens. However, it is unclear whether this association extends to clinical 
symptoms following food consumption [1]. We aimed to determine if 
Table 12 Elevated serum tryptase levels during  reaction according to  severity 
of reaction
Grades of anaphylaxis Elevated tryptase (N) Elevated tryptase %, 
95 % CI
Overall 32/165 19.4 (13.8, 26.4)
Mild 6/32 18.8 (7.8, 37)
Moderate 19/121 15.7 (9.9, 32.7)
Severe 7/12 58.3 (28.6, 83.5)
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SHS exposure during infancy is associated with food hypersensitivity 
from childhood to adolescence.
Methods: Data were obtained from the BAMSE birth cohort of 4089 
Swedish children born in 1994–96 and followed to adolescence [2]. 
SHS exposure in infancy was assessed through parental report when 
the children were 2  months old. Food hypersensitivity was defined 
as the presence of parent-reported symptoms to specific food items 
at 1, 2, 4, 8, 12 and 16  years. Food sensitization was defined as an 
IgE ≥ 0.35 kUA/l to fx5®—a mix of milk, egg, soy, peanut, wheat and 
codfish allergens—at 4, 8 and 16 years.
Odds ratios (OR) and 95 % confidence intervals (95 % CI) from general-
ized estimating equations were used to calculate the overall associa-
tion between SHS exposure in infancy and food hypersensitivity and/
or food sensitization. Estimates were initially adjusted for young mater-
nal age (≤25  years) at birth, exclusive breast feeding (≥4  months), 
parental allergy and socioeconomic status; they were subsequently 
adjusted for concomitant asthma.
Results: SHS exposure in infancy was associated with 1.12 times 
greater odds of reporting food hypersensitivity (OR 1.12; 95 % CI 0.96–
1.30) and 1.29 times greater odds of food sensitization (OR 1.29; 95 % 
CI 1.06–1.57). With respect to concurrent outcomes, SHS exposure in 
infancy was associated with 1.43 times greater odds of having both 
food hypersensitivity and sensitization (OR 1.43; 95  % CI 1.06–1.87); 
this estimate did not change substantially upon adjustment for con-
comitant asthma (OR 1.39; 95 % CI 1.03–1.88).
Conclusions: SHS exposure in infancy is associated with food sensi-
tization from childhood to adolescence, particularly with concurrent 
food hypersensitivity.
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Background: Asthma is a chronic inflammatory disease of the airways. 
Diesel exhaust (DE) is a major contributor to ambient particulate mat-
ter (PM). There is evidence that PM acts as an adjuvant to biological 
allergens and aggravates allergic inflammation [1, 2]. We aim to elu-
cidate if DE increases allergen-induced inflammation and cellular 
immune response in the airways of atopic human subjects.
Methods: We recruited 12 volunteer subjects with allergy to house 
dust mite (HDM), birch or timothy grass. In a randomized blinded, 
crossover design, subjects were exposed to DE (300  µg PM2.5/m
3) or 
filtered air for 2 h. One hour following the exposure, segmental aller-
gen challenge was performed by instilling into contralateral lung seg-
ments through flexible bronchoscopy, either the allergen extract to 
which the participant is sensitive to, or placebo (sterile saline). Endo-
bronchial biopsies from the same segments were then obtained 48 h 
post exposure. Thus, biopsies under four different conditions were 
acquired: filtered air and saline (FAS), DE and saline (DES), filtered air 
and allergen (FAA), and DE and allergen (DEA). Tissue biopsies were 
embedded in glycol methanlacrylate acrylic resin and 2  µm sections 
were cut and used for immunostaining with monoclonal antibodies to 
CD4, interleukin (IL)-4, tryptase and eosinophil cationic protein (ECP). 
Aperio ImageScope software was used to quantify the immunohisto-
chemical staining of positive cells in the bronchial submucosa exclud-
ing smooth muscle and glands.
Results: The percent positivity for CD4 expression significantly 
increased from FAS (0.087  ±  0.018) to DEA (0.311  ±  0.06039; 
p = 0.035) in the bronchial submucosa. The percent positivity for IL-4 
expression elevated from FAS (0.127 ± 0.062) to DEA (0.548 ± 0.143; 
p  =  0.034). The percent positivity for tryptase and ECP expression 
remained unaffected. Data are presented as mean ± SEM.
Conclusions: This data suggest that co-exposure to DE and allergen 
augments CD4+ T cells recruitment and IL-4 expression, thus promot-
ing Th2 polarization in the bronchial submucosa of atopic airways.
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Background: Allergic diseases are the earliest of all chronic diseases 
to develop in children and their prevalence is on the rise [1, 2]. Skin 
prick tests (SPT) are considered an important diagnostic tool for 
allergies [3, 4]. SPT results to a specific allergen are typically calcu-
lated by manual measurement of the wheal of a response. The objec-
tive of this study is to evaluate a new, automated, image-processing 
method for wheal measurements against the standard of manual 
measurements.
The Canadian Healthy Infant Longitudinal Development (CHILD) Study 
is a general population, longitudinal study that focuses on the devel-
opment of allergy in early life. For the purposes of this project, we 
measured SPTs from one-year clinic visits at the Manitoba CHILD site. 
SPTs were performed for common allergens as well as positive and 
negative controls, histamine and glycerine respectively.
Methods: SPTs were performed for 10 common allergens (cat, dog, 
cockroach, D. farinae, D. pteronyssinus, Alternaria, cow’s milk, egg 
white, soybean and peanut) and controls in 1033 children (mean age 
13 ±  2  months). Of the 12,396 tests, there were measurable wheals 
for 1180 SPTs, identified by both automated and manual methods. By 
manual measurements 1105 wheals were ≥2 mm while by the auto-
mated method 1004 were ≥2 mm. Each child’s results were measured 
by hand and by an automated scan and measure system developed 
in our laboratory. The overall diameters averaged 2.94  ±  1.0 (range 
0.5–7.8) by the automated method and 3.52 ± 1.1 (range 0.5–9.3) by 
the manual method with a correlation coefficient of 0.91.
Results: The results demonstrate the value of the automated meas-
urements. The potential advantages of the automated method are 
reproducibility, accuracy, and speed when compared with manual 
measurements.
Page 22 of 28Allergy Asthma Clin Immunol 2016, 12(Suppl 1):22
References
1. Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and man‑
agement of food allergy in the United States: report of the NIAID‑sponsored 
expert panel. J Allergy Clin Immunol. 2010;126(60):S1–58.
2. Eigenmann PA. Breaking frontiers for better early allergy diagnosis. Allergy. 
2004;59(9): 895–6.
3. Celik‑Bilgili S, Mehl A, Verstege A, Staden U, Nocon M, Beyer K, Niggemann 
B. The predictive value of specific immunoglobulin E levels in serum for the 
outcome of oral food challenges. Clin Exp Allergy. 2005;35(3): 268–73.
4. Kanny G, Moneret‑Vautrin DA, Flabbee J, Beaudouin E, Morisse, M, Thevenin 
F. Population study of food allergy in France. J Allergy Clin Immunol. 
2001;108(1):133–40.
A51 
The accurate identification and quantification of urinary biomarkers 
of asthma and COPD through the use of novel DIL‑LC–MS/MS 
methods
Mona M. Khamis1, Hanan Awad1, Kevin Allen1, Darryl J. Adamko2, Anas 
El‑Aneed1
1College of Pharmacy and Nutrition, University of Saskatchewan, 
Saskatoon, SK, Canada, 2College of Medicine, Department of Pediatrics, 
University of Saskatchewan, Saskatoon, SK, Canada
Correspondence: Mona M. Khamis ‑ mmh882@mail.usask.ca  
Allergy, Asthma and Clinical Immunology 2016, 12(Suppl 1):A52
Background: With the growing power of analytical capabilities, tens-
to-hundreds of potential biomarkers are regularly being identified in 
discovery experiments. However, only a limited number has actually 
achieved FDA approval for routine clinical practices. One of the major 
impediment in biomarker discovery pipeline is the lack of coherent 
and well-established assays for subsequent validation steps [1].
Asthma and chronic obstructive pulmonary disease (COPD) are of par-
ticular importance to practitioners due to their overlapping clinical 
presentations. Diagnosis in regular outpatient clinics can be difficult. 
Current diagnostic tests are laborsome, unachievable in some cases, 
and/or insensitive to changes in airway function [2].
Metabolomics has demonstrated promising potential for discovering 
new biomarkers. Urine is an ideal matrix for metabolomic studies due 
to its richness in metabolites and ease of collection. A novel proton 
nuclear magnetic resonance (1H-NMR) study verified 50 polar urinary 
metabolites as candidate biomarkers for the differential diagnosis of 
asthma and COPD patients. Therefore, the next step in the ‘new bio-
marker’ pipeline is to accurately quantify and validate these metabo-
lites with respect to their clinical sensitivity and specificity [2].
Methods: Two liquid chromatography-tandem mass spectrometry 
(LC–MS/MS) methods were developed to simultaneously quantify 34 
metabolites in urine. Differential isotope labeling (DIL) was applied 
using 12C/13C-labeled dimethylaminophenacyl bromide and dansyl 
chloride reagents.
Results: DIL has significantly improved the detection of the polar 
metabolites in urine using a conventional LC–MS/MS platform. Meth-
ods were successfully developed to allow for the quantitative separa-
tion of the target metabolites. The use of structurally identical internal 
standards is an ideal option to correct for matrix effects from indige-
nous compounds within the urine (Fig. 6).
Conclusion: The developed methods are suitable for quantifying 34 
candidate metabolites. Currently, we are validating the LC–MS/MS 
methods according to the FDA guidelines. This will allow us to quantify 
the targeted metabolites in the urine of asthma and COPD patients.
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Background: Allergic rhinitis (AR) is an IgE-mediated inflammatory 
condition of the nasal mucosa induced after allergen exposure [1]. Cat 
allergy affects 10–15 % of patients with allergic rhinitis and/or asthma 
[2]. A novel immunotherapy, Cat-Synthetic Peptide Immuno-Regula-
tory Epitopes (Cat-SPIRE), composed of seven synthetic peptide T-cell 
epitopes, acts on allergen-specific T-cells to induce subsequent clinical 
tolerance to cat allergen.
Methods: In this study, 19 participants with a clinical history of cat 
allergies with significant cat exposure received Cat-SPIRE (4 × 6 nmol 
intradermal injection, 1 dose every 4 weeks). Clinical symptoms were 
Fig. 6 LC‑MS/MS chromatogram of a 12C‑dimethylaminophenacyl‑
labeled metabolites and corresponding 13C‑internal standards and 
b 12C‑dansyl‑labeled metabolites and corresponding 13C‑internal 
standards, in control urine
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assessed by Nasal Allergen Challenge (NAC) [3]. Whole blood was col-
lected into PAXgene tubes at baseline and post NAC (1, 2, and 6  h), 
before and 1  month post treatment. 770 immune genes in the PAX-
gene blood lysates at 6 h post NAC were profiled using the nanoString 
nCounter PanCancer Immune Profiling Panel. After normalization, a 
statistical comparison of pre-versus post-treatment changes was per-
formed and an enrichment pathway analysis undertaken (Enrichr).
Results: 70 immune genes were significantly down regulated com-
pared to pre-treatment at the 6 h post NAC time point (FDR < 10 %). 
These genes were associated with T-cell effector pathways, particularly 
canonical Th2 cytokines such as IL-4, IL-5, IL-3, IL-6 and TSLP. These 
changes were accompanied by significant post- versus pre-treatment 
reductions in clinical symptoms, Total Nasal Symptom Score and Peak 
Nasal Inspiratory Flow.
Conclusion: Following Cat-SPIRE treatment, systemic immune path-
ways of T-cell effectors were changed in peripheral blood of cat 
exposed, allergic individuals. The effect on these pathways provides 
insight towards the mechanism by which Cat-SPIRE induces immune 
tolerance. Whole blood immune transcriptome profiling in larger 
sample sizes and/or various time points after NAC may provide bio-
markers or tools to discover the immune response or tolerance 
mechanism.
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Background: Children of low-income families access more urgent care 
and less preventive care for asthma [1]. Children with a respiratory dis-
ease from low-income families also experience a lower quality of life 
[2, 3]. Our previous online peer/professional support programs have 
improved children’s asthma and allergy self-management skills, and 
decreased loneliness [4–8]. However, in our previous programs, partici-
pants’ have come from high-income families [4–8]. Consequently, the 
objective of this research was to determine low-income participants’ 
perceptions of the impact of the support intervention, the factors 
influencing these impacts, their satisfaction with the intervention, and 
recommended changes.
Methods: Peer and professional mentors who lived with asthma and 
allergies and had experience with vulnerable families were recruited 
and trained to facilitate sessions. Participants in the cohort included 16 
children aged 7–11, and adolescents 12–17 from across Canada. Chil-
dren were provided with internet services for the program duration, 
chromebooks, and headsets/microphones that they could keep. Eight 
weekly meetings were offered on the Internet using GoToMeeting®; a 
secure online meeting platform. Quantitative data on health-related 
outcomes were elicited by standardized measures administered pre- 
and post-intervention. Qualitative data on the intervention processes 
was also collected.
Results: Preliminary analysis post-intervention, has shown an increase 
in coping skills and perceived support, and reduced loneliness after 
participating in the online sessions. Even more significant, in compari-
son to online programs with higher income families, was the increased 
understanding and appreciation of asthma/allergy triggers in par-
ticipants. They also learned new ways to manage their triggers. Many 
parents reported that their children were less resistant to taking their 
medication and had a higher adherence to medication post-interven-
tion due to an increased understanding about their medications and 
use.
Conclusion: It is evident that online-peer-support programs for lower 
income families require a different focus compared to programs devel-
oped for higher income families, as they face different challenges and 
have different needs.
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Background: Asthma is a chronic respiratory disease involving 
genetic and environmental interactions [1, 2]. More than 300 genes 
have been associated with asthma or related phenotypes, and the 
number continues to increase [3]. The associated common SNPs rep-
resent a small part of the genetic component and the exact nature of 
the causal genetic variants remains to be discovered [4]. One reason 
for this “missing heritability” is that many genetic factors act primar-
ily through complex mechanisms involving interactions with other 
genes and environmental factors and/or epigenetic mechanisms [5]. 
We have shown that genetic variants related to asthma can be mech-
anistically studied using epigenetic and functional genomic assess-
ment of individual variants [6, 7]. Therefore, we plan to focus on IL33 
pathway following the previous study demonstrating a correlation 
between methylation signature, expression and asthma in bronchial 
epithelial cells.
Method: DNA methylation (Δβ) has been measured with an 
epigenome wide association study (EWAS) using Illumina 
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HumanMethylation450K arrays among 69 asthmatic individuals and 
91 controls. Data were extracted for 21,720 genes including 26 in 
the pathway of IL33 and the association with asthma was assessed 
by logistic regression using methylation percentage, asthma pheno-
type, sex, age, IgE level, smoking status and eosinophils, lymphocytes, 
monocytes, neutrophils, and basophils counts as covariates. Batch 
effect was corrected for the analysis.
Results: A total of four genes have demonstrated a significant differ-
ence of methylation between asthmatic individuals and control ones: 
CLSTN2 (Δβ  =  7.35  %, p  =  0.0008), CDSN (Δβ  =  7.39  %, p  =  0.02), 
PSORS1C1 (Δβ = 7.39 %, p = 0.02) and CCDC57 (Δβ = 5.63 %, p = 0.02).
Conclusion: This study shows differences in methylation marks 
between asthmatic individuals and non-asthmatic non-allergic con-
trols for four genes (CLSTN2, CDSN, PSORS1C1, CCDC57). Interestingly, 
PSORS1C1, a susceptibility gene for psoriasis, has already been associ-
ated with asthma in a genome wide association study in Latino chil-
dren [8]. The pyrosequencing of this gene will allow us to confirm this 
association.
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Background: Sterile inflammation is a major mechanism by which tis-
sue damage occurs throughout the body and is also a major determi-
nant of disease progression. It is initiated after sterile physical damage 
has occurred in local tissues, but can also be initiated in a number of 
inflammatory disorders, such as asthma and arthritis. Many different 
cell types appear to be involved in sterile inflammation, but the role of 
mast cells has been of particular interest. Mast cells are innate immune 
sentinel cells that reside in many tissues throughout the body that 
synthesize and secrete many pro- and anti-inflammatory mediators. 
The alarmin IL-33 is an important component of the sterile inflamma-
tory process and has been shown to directly activate populations of 
mast cells [1, 2]. Furthermore, IL-33 has been implicated as a potential 
early-life predictor of childhood asthma and allergy [3]. Therefore, the 
purpose of this study was to determine the cytokine and chemokine 
profile of human mast cells activated with IL-33.
Methods: Cord blood-derived mast cells (CBMCs) were activated for 
24  h with IL-33 at a concentration of 30  ng/mL. To analyse protein 
production from CBMCs, supernatants were collected and a Luminex 
assay was conducted to analyse the concentration of 29 cytokines and 
chemokines. Additionally, gene expression data was analyzed through 
qPCR to determine gene expression changes upon activation of mast 
cells with IL-33.
Results: It was found that after IL-33 activation, CBMCs had a sta-
tistically significant increase in production of IL-13, but not other 
TH2-related cytokines such as IL-4. There was no increase in produc-
tion of TH1-related cytokines, such as IFNγ and IL-12. Production of 
the cytokines VEGF and GM-CSF were also statistically significantly 
increased after IL-33 activation of CBMCs.
Conclusions: In conclusion, IL-33 activation of human mast cells 
results in the production of cytokines supportive of TH2-driven 
responses and tissue regeneration.
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Background: Lung clearance index (LCI), a parameter derived from 
the multiple breath washout (MBW) test, is a sensitive marker of venti-
lation inhomogeneity and has been associated with early lung disease. 
Appropriate representative normative reference data must be avail-
able to correctly interpret individual lung function results. We aim to 
develop a novel Canadian reference equation for LCI and compare it to 
previously published reference equations.
Methods: Two hundred and sixty-five subjects underwent MBW meas-
urement using an AMIS mass spectrometer and 4 % SF6 as a tracer gas. 
All subjects were free of prior respiratory distress and had no history 
of wheezing or exposure to maternal smoking during pregnancy. For 
subjects under 4 years of age, data were obtained from 196 subjects 
recruited from the Canadian Healthy Infant Longitudinal Development 
(CHILD) Study. For subjects aged 4–15 years, data were obtained from 
69 identified healthy controls. The lamda-mu-sigma (LMS) method was 
used to construct reference equation, with LCI modelling in terms of 
age and height.
Results: LCI was found to be independent of race and gender. Com-
pared with reference equation from Lum et  al. [1], predicted median 
LCI based on our reference equation was 0.41 [95  % confidence 
interval (CI) 0.39–0.43] lower. During infancy to 4  years of age, LCI 
decreased non-linearly as age and height increased (Table  13). After 
4  years of age, LCI remained constant with a mean (standard devia-
tion) of 6.15 (0.39), regardless of change in age and body size. This 
change in LCI values was associated with a decreased misclassifica-
tion rate. In a group of well controlled asthmatics from our clinic, 25 % 
(9/36) subjects had an abnormal LCI when using our reference equa-
tion while only 11 % (4/36) were identified using the Lum et al. refer-
ence equation.
Conclusions: Population-specific equations are necessary for the 
proper interpretation of clinical results.
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Background: The Kingston allergy birth cohort (KABC) was instigated 
to study the role of gene-environment interactions and epigenetic 
modifications in the developmental origins of allergy. Kingston Gen-
eral Hospital was chosen as the collection site, as it serves rural/urban 
residents with diverse socioeconomic status and has documented 
challenges such as a high rate of maternal smoking.
Methods: Pregnant women completed a health/environmental sur-
vey (n = 594). Umbilical cord blood was collected from 454 deliveries 
and environment/health surveys to age 2 encompassing 327  years 
of person-time from 235 children. We examined home-environment 
characteristics by urban/rural residence and socioeconomic status 
(SES; National Household Survey). Exposure to smoke was active/
passive  >3  days/week. For rates of parentally-reported skin, respira-
tory and food symptoms of potential allergic disease, only wheezing/
coughing not associated with illness, and rashes that were not cradle 
cap, diaper rash or infectious were considered.
Results: Maternal and both-parent allergies were self-reported in 27.5, 
and 22.3 %. The KABC encompassed a high proportion of rural residents 
(41.3  %) and mothers exposed to smoke (25.9  %). Rural participants 
had significantly higher household income, less post-secondary edu-
cation, more fireplace use, and more indoor dogs. Urban participants 
were significantly more likely to live near a major road. The homes of 
lowest-tertile-SES participants were significantly older, more likely to be 
apartment-style and to be located near a major road, relative to highest-
tertile-SES. However, low-SES participants were significantly less likely to 
cook with gas, have a fireplace or an attached garage. The rate of devel-
opment of parentally-reported skin, respiratory and food reactions in 
the KABC was 0.36, 0.17, and 0.17 cases/person-year, respectively.
Conclusions: We found that both residing in rural/urban and high/
low-SES areas affected characteristics of the home and potential envi-
ronmental exposures. Further analyses will explore rate differences 
between children with various exposures. Mother/child pairs are 
returning for skin testing and epigenetic analysis of umbilical cord and 
peripheral blood.
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Background: Cow’s milk allergy (CMA) is defined as immunologic 
adverse reactions to cow’s milk proteins (CMP). It affects 2–3  % of 
infants [1]. Approximately 15  % of the CMA population retains their 
allergic status even after 8 years of age [2].
Methods: Twenty patients were recruited in a case control study of 
cow’s milk (CM) oral immunotherapy (OIT). Blood samples were col-
lected at baseline and at multiple timepoints during the trial. Specific 
IgE, IgA and IgG4 to casein, β-lactoglobulin (BLG) and α-lactalbumin 
(ALA) were measured in OIT recipients (n = 9) by using Enzyme-Linked 
Immunosorbent Assays (ELISA).
Results: CMP-sIgE decreased multiple times baseline in 6 of 9 OIT 
recipients, remained high in 2 subjects, and unaltered in 1 individual 
due to OIT (data not shown). At the same time, specific IgA and spe-
cific IgG4 increased (Fig. 7) in parallel with the decrease in CMP-sIgE. 
Specific IgA increased significantly baseline in 7 of 9 patients in case 
of casein, and in 6 of 9 patients in case of BLG and ALA. Again, specific 
IgG4 to casein increased significantly baseline in 8 of 9 patients, and in 
all 9 patients in case of BLG and ALA.
Conclusions: In summary, a significant decrease in CMP-sIgE and a 
concomitant increase in CMP-sIgA and -IgG4 were observed in suc-
cessful CM OIT recipients. These findings demand an extensive study 
of pro-inflammatory (e.g. T-helper cells) and anti-inflammatory cells 
(e.g. T- and B-regulatory cells) along with their secreted cytokines to 
elucidate the mechanism of the development of tolerance in CM OIT.
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Table 13 Reference equation for  lung clearance index (LCI) from  infancy 
to 15 years of age
Age ≤4 Age >4
Skewness (L) −2.12 –
Predicted (M) 6.88–6.95 (Age/10)2 − 1.16 [(log Length)/10]3 6.15
Coefficient of variance (S) 0.07 –
Upper limited of normal (ULN) Predicted × [(1.96 × 0.07 × (−2.12))  
+ 1]1/−2.12
6.91
Fig. 7 CMP‑specific IgA to casein (a) and ALA (c) increased signifi‑
cantly from pre‑therapy to 300 mL challenge with CM (unpaired t 
test, **P < 0.01 and *P < 0.05 respectively for casein and ALA). Casein 
(d), BLG (e), and ALA (f) specific IgG4 increased significantly baseline 
at the completion of OIT (unpaired t test, *p < 0.05, ***p < 0.001, 
***p < 0.001 respectively for casein, BLG, and ALA)
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Background: Sensitization to peanut places a child at risk for anaphy-
laxis to peanut, although some peanut-sensitized children tolerate 
eating peanut. We evaluated the association between timing of pea-
nut introduction in infancy and development of reactions and sensiti-
zation to peanut by age 3 years.
Methods: Caregivers of participants in the population-based Cana-
dian Healthy Infant Longitudinal Development (CHILD) Study prospec-
tively reported their child’s first introduction and reactions to peanut 
starting at age 6  months. At ages 1 and 3  years, the children under-
went skin prick testing for sensitization to peanut and other food aller-
gens, and an assessment for eczema/atopic dermatitis. We conducted 
multivariable logistic regression to determine if later introduction of 
peanut was associated with increased odds of reactions and sensitiza-
tion to peanut.
Results: Among participants from the Manitoba and Vancouver sites 
(n =  1610), peanut was introduced into the diet at ages 6 (1.3  %), 9 
(14.1  %), 12 (27.4  %) and  >12 (42.3  %) months; 14.9  % had not tried 
peanut by 18 months. At age 1 year, 2.4 % of children had moderate-
to-severe eczema. By age 3 years, 5.6 % of children had a reaction to 
peanut and 7.2 % had at least one positive skin prick test to peanut, 
3.4 % to milk, and 9.3 % to egg. In the first 3 years, 53.9 % of peanut-
sensitized children had reacted to peanut and 77.8 % of children who 
had reacted to peanut were peanut-sensitized. Children with later 
peanut introduction (on a continuous scale from 6–18  months) had 
higher odds of a reaction (1.04; 95  % CI 1.02–1.06) and sensitization 
(1.04; 1.03–1.05) to peanut, after adjustment for sensitization to egg 
and moderate-to-severe eczema.
Conclusion: In a population-based sample of Canadian children, later 
peanut introduction was associated with reported reactions and sen-
sitization to peanut by age 3 years. Further investigation is needed to 
characterize the association between timing of peanut introduction 
and persistent peanut allergy.
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Background: Individuals with allergic asthma respond differently, 
but reproducibly, to allergen inhalation challenge. Some individuals 
develop an isolated early response (early responders, ERs) while oth-
ers also go on to develop a late response (dual responders, DRs). Since 
new drugs for allergic asthma are targeted towards attenuating the 
late phase response, the purpose of this study is to identify a multi-
omic biomarker panel that can screen mild asthmatics for those likely 
to exhibit the late response.
Methods: 32 individuals participated in the allergen inhalation chal-
lenge as part of the AllerGen clinical investigator collaborative. 15 (17) 
participants were classified as ERs (DRs), respectively. Blood samples 
were collected prior to the allergen inhalation challenge. Measure-
ments of cell counts were obtained using a hematolyzer; gene tran-
script relative levels using RNA sequencing; metabolite levels using 
tandem mass spectrometry. Sparse generalized canonical correlation 
discriminant analysis was used to classify ERs and DRs by integrating 
all three datasets, adjusting for age, sex and allergen. Geneset enrich-
ment analysis was performed using Enrichr.
Results: After pre-processing and filtering, 5 cell-types, 11,879 gene 
transcripts and 124 metabolites were retained for downstream analy-
sis. The multi-signature classifier consisted of 2 cell-types, 10 gene 
transcripts and 10 metabolites and had an error rate of 20  ±  8.3  % 
(10 × 5-fold cross-validation). The cells selected in the multi-signature 
panel included lymphocytes and monocytes. The selected metabolites 
were enriched for phosphatidylcholines. The top 10 enriched path-
ways in the selected gene transcripts included the phosphatidylinosi-
tol signalling system.
Conclusions: Molecular signatures in blood can be used to screen for 
asthmatic individuals that develop the late asthmatic response. This 
study implicates the arachidonic acid metabolism pathway in leading 
to the early or late phase asthmatic response.
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Background: Asthma is the most prevalent childhood disease affecting 
over 300 million people worldwide. Our research group previously asso-
ciated features of the early life gut microbiota (at 3 months and 1 year of 
age) in children with risk of active asthma at school age (determined by 
the asthma predictive index). These features included underrepresenta-
tion of four bacterial genera and a decreased production of microbial 
derived metabolites. We hypothesize that this constitutes a dysbiotic 
early life microbiota, which is also associated with asthma diagnosed in 
children by 3 years of age and sought to identify additional bacterial taxa 
that may be associated with this asthmatic phenotype.
Methods: 287 children enrolled in the Canadian Healthy Infant Lon-
gitudinal Development (CHILD) Study were classified according to 
the diagnosis of asthma by 3  years of age. Bacterial 16S rDNA from 
3-month and 1-year stool samples from these children was extracted, 
amplified, and subjected to high throughput Illumina sequencing. 
Specific bacterial genera and species were quantified by quantitative 
PCR from all children with asthma and a subset of controls with no his-
tory of asthma symptoms. An exact logistic regression model was used 
to assess the effects of potentially confounding variables (i.e. antibiotic 
exposure, mode of birth).
Results: 16S sequence analysis of our sample cohort identified dif-
ferentially abundant bacterial populations between asthmatics and 
controls in stool collected at 3 months and 1 year of age. Additionally, 
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qPCR identified significant shifts in the abundance of specific bacterial 
genera in stool collected at 3  months and 1  year of age in the asth-
matic group when compared to controls.
Conclusions: Shifts in the relative abundance of specific gut bacterial 
populations in early life are associated with asthma diagnosed in chil-
dren by 3 years of age.
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Background: The relationship between immunoglobulin E (IgE)-
mediated food sensitization and the development of atopic dermatitis 
during infancy is not well-characterized. Past studies have shown that 
food sensitization is associated with the occurrence of atopic diseases 
[1–3], including atopic dermatitis, although this relationship has not 
been examined in a population-based birth cohort at 1 year. Our aim 
was to address this knowledge gap by analyzing results from nearly 
3000 children enrolled in the Canadian Healthy Infant Longitudinal 
Development (CHILD) Study.
Methods: An algorithm based on Child Health questionnaires com-
pleted by parents when their children were 1  year old was used to 
classify children as having definite, possible, or no atopic dermatitis. 
Atopic dermatitis classification was cross-tabulated with skin prick test 
(SPT) results to food allergens, specifically peanut, milk, egg, and soy-
bean. A positive SPT was defined by a wheal diameter of ≥2 mm com-
pared to the negative control. In total, 2626 children who underwent 
skin testing and had corresponding questionnaire data were included 
in this project.
Results: Of 2626 children, 526 (20.0 %) had definite atopic dermatitis 
and 906 (34.5 %) had possible atopic dermatitis (Table 14). There was 
an increasing trend in the proportion of positive SPTs with increas-
ing certainty of atopic dermatitis (Cochran-Armitage trend test, 
p  <  0.001). Sensitization to any food allergen was associated with 
higher odds of having definite or possible atopic dermatitis (OR 2.04, 
95  % CI 1.64–2.53). Specifically, sensitization to peanut (p  <  0.0001), 
egg (p < 0.0001), and milk (p = 0.0021) were significantly associated 
with atopic dermatitis, but sensitization to soybean (p = 0.3470) was 
not.
Conclusions: IgE-mediated sensitization to any food allergen at 
1  year was associated with higher odds of having definite or pos-
sible atopic dermatitis. Sensitization to peanut, egg white, and 
milk, but not soybean, were significantly associated with atopic 
dermatitis.
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Background: Hematopoietic progenitor cells (HPCs) may act as pro-
inflammatory effector cells by themselves and directly contribute to 
allergic inflammation. HPCs express the receptor for thymic stromal 
lymphopoietin (TSLPR) and respond TSLP by rapidly releasing high lev-
els of pro-inflammatory Th2-like cytokines and chemokines. HPCs also 
express toll-like receptors (TLRs)-2, -4 and -9, and TLR ligation induces 
eosinophil-basophil differentiation from HPCs. In the current study we 
investigated the effects of allergen inhalation on TLR-induced TSLPR 
expression by HPCs.
Methods: Seven mild allergic asthmatics underwent bronchial aller-
gen challenges. All subjects developed a dual response to inhaled 
allergen. Blood was collected before and 24  h after the challenge. 
CD34-enriched peripheral blood (pb) cell populations were stimulated 
with TLR-2 (lipoteichoic acid, LTA), TLR-4 (lipopolysaccharide, LPS) or 
TLR-9 (ODN2006) ligands. TLR expression by pb HPCs as well as TSLPR 
expression by HPCs stimulated with TLR agonists pre- and post-chal-
lenge were measured by flow cytometry.
Results: There was no significant change in TLR-2, TLR-4 or TLR-9 expres-
sion post allergen inhalation. TSLPR was barely detected on unstimulated 
HPCs. However, overnight stimulation of HPCs with LPS and ODN2006 
induced a significant increase in TSLPR expression compared with 
unstimulated HPCs (p < 0.01 and p < 0.05, respectively). In addition, LPS- 
and ODN2006-induced TSLPR expression by HPCs was more pronounced 
post-allergen compared to baseline (p < 0.001 and p < 0.05, respectively). 
No significant effect of LTA on TSLPR expression was noted.
Conclusions: Allergen exposure changes the response of HPCs to TLR 
stimulation by enhancing TSLP (and thus pro-inflammatory) respon-
siveness. These findings suggest that HPCs may be relevant in the 
pathogenesis of pathogen-related asthma exacerbations.
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Background: The allergic rhinitis clinical investigator collaborative 
(AR-CIC) is a national initiative conducting standardized nasal allergen 
challenges (NAC) to investigate the effectiveness of therapeutic agents 
for allergic rhinitis (AR), as well as analyze biomarkers and potential 
Table 14 Cross-tabulation of  food sensitization and  atopic dermatitis classifica-
tion
SPT results Atopic dermatitis classification
Definite Possible No Total













Total 526 906 1194 2626
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pathways of the allergic response. The NAC involves direct exposure of 
the nasal mucosa to the allergen of interest and evaluation of clinical, 
cellular and molecular outcomes.
Methods: 10 ragweed allergic participants, with a history of AR and 
a skin prick test to short ragweed  ≥3  mm than the negative con-
trol, were enrolled. Participants were screened for inclusion/exclu-
sion criteria and their qualifying allergen concentration determined. 
Participants returned 21–28  days later and received the cumulative 
allergen concentration on two NAC visits separated by 21 days. Nasal 
lavage samples were collected at baseline, 1, 6, and 24 h after allergen 
challenge. The samples were kept on ice until cytospin slides were 
prepared and stained with Diff-Quik™. Differential cell counts were 
completed for each sample to determine the eosinophil fraction as a 
percent of the total white blood cells. GraphPad Prism™ was used for 
all statistical analysis.
Results: Starting at 1  h, there was an increase in eosinophils after 
NAC which was significant at 24 h at both NAC visits (p ≤ 0.05). When 
compared to non-allergic controls, obtained previously under similar 
study conditions, a significant increase in the eosinophil population of 
allergic participants was observed for both NAC visits at 1 and 6 h post 
NAC time points (p ≤ 0.05). 24-hour samples for non-allergics were not 
collected in the previous study. No significant differences were iden-
tified between the consecutive NAC visits concerning eosinophil frac-
tion in allergics at any time point.
Conclusions: There were no significant differences in eosinophil frac-
tion between the two NAC visits, indicating repeatability of nasal 
eosinophilia using the repeated cumulative allergen challenges 
(RCAC) protocol.
A65 
The CHILD Study: optimizing subject retention in pediatric 
longitudinal cohort research
Linda Warner1, Mary Ann Mauro1, Robby Mamonluk1, Stuart E. Turvey1
1Department of Pediatrics, University of British Columbia, Vancouver, BC, 
Canada
Correspondence: Linda Warner ‑ lwarner@cfri.ca  
Allergy, Asthma and Clinical Immunology 2016, 12(Suppl 1):A66
Background: The Canadian Healthy Infant Longitudinal Development 
(CHILD) Study is a multicentre birth cohort study following children for 
at least the first 5  years of life to determine how environmental and 
genetic variables impact health, and particularly the development of 
asthma, eczema, and allergies. Subject retention is essential for opti-
mal scientific integrity.
Methods: Vancouver-based participants completed surveys after 
1 and 5 years. The 1-year surveys focused on what was important to 
families for their continued participation and reasons for potential 
withdrawal (reported at the 2013 Canadian Society of Allergy and 
Clinical Immunology Scientific Meeting). The 5-year surveys reassessed 
reasons for ongoing participation and evaluated retention strategies.
Results: The first 79 subjects, due for the 5-year clinic visit, were ana-
lyzed through April 2015: 69/79 (87 %) completed the visit, 1/79 (1 %) 
transferred to the Toronto site, 3/79 (4  %) booked future visits, and 
efforts to schedule the remaining 5/79 (6 %) are ongoing. Importantly, 
no participants have been lost to follow-up at this stage, including 15 
families who moved outside of Vancouver. Of the 69 visits completed: 
57/68 (84 %) of blood samples were collected, including only 2 refus-
als and 10 failures related to lab closure; 68/69 (99 %) of urine samples 
were collected; 69/69 (100  %) skin prick tests were completed; and 
68/69 (99 %) spirometry assessments were completed.
From survey data, parents identified their highest priority for study 
participation as: desire to improve child health globally (68  %), a 
positive experience for the child (19 %), ease of online questionnaires 
(6  %), monetary reimbursement (4  %) and flexibility in scheduling 
(2 %).
Conclusion: Successfully engaging participants is crucial to achiev-
ing study objectives, particularly in a pediatric longitudinal study 
where there is a high likelihood for change over time. In our Vancou-
ver experience, ongoing engagement with families through surveys 
has ensured that challenges are identified and addressed during the 
course of the study. Ultimately, active participant engagement in the 
CHILD Study likely enhanced subject retention and protocol comple-
tion to optimize scientific integrity.
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Background: Allergic asthma is an airway inflammatory disease char-
acterized by airway obstruction, increasing bronchovascular perme-
ability, and airway hyperresponsiveness. Two phenotypes—early 
responders (ER), who only experience an acute bronchoconstriction 
within minutes following the allergen exposure, and dual responders 
(DR), who also experience a further longer-lasting bronchoconstric-
tion several hours after the initial exposure—are involved in the dis-
ease, but the mechanism that leads to the two phenotypes remains 
elusive. Activation of the complement system, which is part of innate 
immunity, is strongly associated with the disease. Various models have 
shown that the complement anaphylatoxins, C3a and C5a, play an 
important role in regulating the allergic response owing to their pro-
inflammatory effects [1]. Therefore, we hypothesized that C3a and C5a 
are differentially abundant in plasma of ERs, DRs and non-asthmatic 
controls.
Methods: 14 mild asthmatic and 6 non-asthmatic control individu-
als participated in our study. Peripheral whole blood samples were 
collected using EDTA tubes and the samples were further processed 
to obtain plasma. Quidel MicroVue™ C3a Plus and C5a EIA kits were 
used to measure C3a and C5a expression levels, respectively. Student’s 
t-tests were then used to compare C3a and C5a levels in plasma of ERs, 
DRs and non-asthmatic controls.
Results: C3a levels were lower in controls compared to ERs (p < 0.01) 
and DRs (p  <  0.05) but there was no significant difference between 
ERs and DRs. C5a levels were up-regulated in ERs compared to DRs 
(p  <  0.01) and controls (p  <  0.05). The down-regulation of C5a in 
DRs may be due to the fact that C5a is protective during allergen 
sensitization.
Conclusions: Both C3a and C5a expression levels are associated with 
allergic asthma. C3a is lower in non-asthmatics compared to ERs and 
DRs; C5a is higher in ERs compared to DRs and non-asthmatics. Further 
validation is ongoing.
Reference
1.  Zhang X, Kohl J. A complex role of complement in allergic asthma. Expert 
Rev Clin Immunol. 2010;6(2):269–77.
